<?php

namespace Database\Seeders;

use App\Models\EducationPost;
use App\Models\ProductCategory;
use Illuminate\Database\Seeder;

class EncyclopediaArticlesBatch3Seeder extends Seeder
{
    public function run(): void
    {
        $articles = $this->getArticles();

        foreach ($articles as $slug => $data) {
            $category = ProductCategory::where('slug', $slug)->first();
            if (!$category) {
                $this->command?->warn("Category not found: {$slug}");
                continue;
            }

            // Skip if already has a published article
            $existing = EducationPost::where('product_category_id', $category->id)
                ->where('status', 'published')
                ->first();
            if ($existing) {
                $this->command?->info("Skipping {$data['title']} — already has article");
                continue;
            }

            EducationPost::updateOrCreate(
                ['product_category_id' => $category->id],
                array_merge($data, [
                    'slug' => $slug,
                    'status' => 'published',
                    'published_at' => now(),
                    'storage' => 'Refrigerate at 2-8°C (36-46°F). Freeze lyophilized form for long-term storage.',
                ])
            );

            $this->command?->info("Created article: {$data['title']}");
        }
    }

    private function getArticles(): array
    {
        return [

            // ──────────────────────────────────────────────
            // 1. GHK Basic
            // ──────────────────────────────────────────────
            'ghk-basic' => [
                'title' => 'GHK Basic',
                'peptide_full_name' => 'Glycyl-L-Histidyl-L-Lysine',
                'research_title' => 'GHK: A Comprehensive Research Overview of the Copper-Binding Tripeptide',
                'research_outline' => 'An in-depth analysis of GHK, a naturally occurring tripeptide with copper-binding affinity, covering its role in wound healing, extracellular matrix remodeling, and gene expression modulation in preclinical research.',
                'education_tag' => 'Copper Peptides',
                'description' => 'GHK (Gly-His-Lys) is a naturally occurring tripeptide first isolated from human plasma by Loren Pickart in 1973. It possesses a strong affinity for copper(II) ions, forming the GHK-Cu complex. Research has identified GHK as a signaling molecule involved in wound repair, collagen synthesis, and broad gene expression modulation affecting tissue remodeling pathways.',
                'molecular_formula' => 'C₁₄H₂₄N₆O₄',
                'molecular_weight' => '340.38 g/mol',
                'half_life' => 'Minutes to hours (varies with copper complexation state)',
                'bioavailability' => 'Dependent on formulation and route of administration in research settings',
                'background' => 'GHK (glycyl-L-histidyl-L-lysine) is a tripeptide naturally present in human plasma, saliva, and urine. It was first identified by Loren Pickart in 1973 during studies of human albumin fractions that stimulated hepatocyte growth. The peptide is released during tissue injury through proteolytic degradation of extracellular matrix proteins such as collagen and SPARC (secreted protein acidic and rich in cysteine). GHK has a high affinity for copper(II) ions, and the resulting GHK-Cu complex is the predominant bioactive form. Plasma levels of GHK decline with age — from approximately 200 ng/mL at age 20 to roughly 80 ng/mL by age 60 — which has prompted research interest in its role in age-associated decline in tissue repair capacity. Broad gene expression studies have demonstrated that GHK can modulate the activity of numerous genes involved in tissue remodeling, antioxidant defense, and anti-inflammatory responses.',
                'mechanism_of_action_intro' => 'GHK exerts its biological effects through multiple interconnected mechanisms, primarily centered on copper ion delivery, extracellular matrix remodeling, and gene expression regulation.',
                'mechanism_subsections' => json_encode([
                    [
                        'intro' => 'The biological activity of GHK involves copper-dependent and copper-independent signaling pathways that converge on tissue remodeling and repair processes.',
                        'points' => [
                            'Binds copper(II) with high affinity (log stability constant ~16.44), delivering bioavailable copper to cells for enzymatic processes including lysyl oxidase-mediated collagen crosslinking',
                            'Stimulates collagen I, collagen III, and glycosaminoglycan synthesis in dermal fibroblast cultures',
                            'Activates the ubiquitin-proteasome pathway, promoting turnover of damaged extracellular matrix components',
                            'Modulates gene expression broadly — Broad Institute Connectivity Map analysis identified over 4,000 genes responsive to GHK, including upregulation of DNA repair genes and antioxidant response elements',
                            'Stimulates metalloproteinase activity for controlled matrix remodeling while simultaneously promoting new collagen deposition',
                        ],
                    ],
                ]),
                'preclinical_intro' => 'GHK and its copper complex have been studied extensively in cell culture systems, tissue models, and animal wound healing experiments over several decades.',
                'preclinical_subsections' => json_encode([
                    [
                        'title' => 'Wound Healing and Tissue Repair',
                        'findings' => [
                            ['title' => 'Collagen Synthesis', 'description' => 'In cultured human dermal fibroblasts, GHK-Cu stimulates the synthesis of collagen types I and III, decorin, and other extracellular matrix components. Studies demonstrate increased procollagen secretion at nanomolar concentrations.'],
                            ['title' => 'Animal Wound Models', 'description' => 'In rodent wound healing studies, topical application of GHK-Cu accelerated wound contraction, increased granulation tissue formation, and enhanced angiogenesis within the wound bed.'],
                        ],
                    ],
                    [
                        'title' => 'Gene Expression and Genomic Studies',
                        'findings' => [
                            ['title' => 'Connectivity Map Analysis', 'description' => 'Broad Institute analyses revealed that GHK modulates the expression of over 4,000 human genes, with significant upregulation of genes associated with DNA repair (ERCC and GADD family members) and suppression of genes linked to inflammatory signaling.'],
                            ['title' => 'Antioxidant Response', 'description' => 'GHK treatment in cell models has been associated with increased expression of antioxidant enzymes including superoxide dismutase and genes within the Nrf2 pathway.'],
                        ],
                    ],
                ]),
                'preclinical_disclaimer' => 'All findings are from cell culture and animal studies. GHK has not been evaluated in controlled human clinical trials for therapeutic endpoints. In-vitro results may not translate to in-vivo human outcomes.',
                'human_use_intro' => 'No controlled clinical trials evaluating GHK as a standalone therapeutic agent have been published. However, GHK-Cu has been incorporated into cosmetic formulations that have undergone limited human observational studies.',
                'human_use_subsections' => json_encode([['title' => 'Clinical Evidence', 'entries' => [['type' => 'content', 'value' => 'GHK-Cu has been included in commercial skincare products, and limited observational studies have reported improvements in skin firmness, fine lines, and photoaged skin appearance. However, these studies typically lack rigorous controls, randomization, and blinding, making definitive conclusions difficult.']]]]),
                'regulatory_subsections' => json_encode([['title' => 'Regulatory Status', 'entries' => [['type' => 'content', 'value' => 'GHK is not approved by the FDA or EMA as a therapeutic agent. It is used as a cosmetic ingredient (INCI: Tripeptide-1) in topical formulations. Research-grade GHK is sold for in-vitro laboratory and research purposes only (RUO).']]]]),
                'regulatory_important_note' => 'Research-grade GHK is an experimental compound sold for laboratory research purposes only. It is not approved for therapeutic use or self-administration.',
                'potential_applications_intro' => 'Preclinical evidence suggests several areas where GHK research may have continued relevance.',
                'potential_applications' => json_encode([
                    ['title' => 'Wound Healing Biology', 'description' => 'GHK-Cu is studied as a model compound for understanding copper-dependent tissue repair and ECM remodeling mechanisms.'],
                    ['title' => 'Gene Expression Research', 'description' => 'The broad gene-modulatory effects of GHK make it a tool for studying coordinated transcriptional programs in tissue homeostasis.'],
                    ['title' => 'Skin Biology and Aging Research', 'description' => 'The age-related decline in plasma GHK levels and its effects on dermal fibroblasts make it relevant to skin aging research models.'],
                ]),
                'potential_applications_important_context' => 'All potential applications are based on preclinical and in-vitro research. No therapeutic claims are made.',
                'conclusion' => 'GHK is a naturally occurring tripeptide with a remarkable breadth of biological activity centered on its copper-binding capacity and gene expression modulatory effects. Its identification in human plasma and its role in tissue injury signaling have made it an important research tool for understanding wound healing, ECM dynamics, and age-related tissue changes. Genomic analyses revealing modulation of thousands of genes suggest a role as a broad biological signal rather than a single-pathway effector. Despite extensive preclinical investigation, GHK has not been subjected to rigorous controlled human clinical trials, and its applications remain within the domains of laboratory research and cosmetic science.',
                'references' => json_encode([
                    ['title' => 'Journal of Biological Chemistry (1973)', 'authors' => 'Pickart L, Thaler MM.', 'links' => []],
                    ['title' => 'BioMed Research International (2014)', 'authors' => 'Pickart L, Vasquez-Soltero JM, Margolina A.', 'links' => []],
                    ['title' => 'Gene (2012)', 'authors' => 'Pickart L, Vasquez-Soltero JM, Margolina A.', 'links' => []],
                ]),
                'key_points' => json_encode(['GHK is a naturally occurring tripeptide (Gly-His-Lys) first isolated from human plasma in 1973', 'Forms a high-affinity complex with copper(II) ions that is the primary bioactive form', 'Modulates expression of over 4,000 human genes involved in tissue repair and antioxidant defense', 'Not approved for therapeutic use — research use only (RUO)']),
                'overview' => 'GHK is a copper-binding tripeptide involved in wound healing, collagen synthesis, and broad gene expression modulation in preclinical research.',
                'areas_of_research_intro' => 'GHK research spans wound biology, dermatology, genomics, and extracellular matrix biochemistry.',
                'areas_of_research' => json_encode([
                    ['name' => 'Wound Biology', 'description' => 'Copper-dependent tissue repair and ECM remodeling'],
                    ['name' => 'Skin Aging Research', 'description' => 'Fibroblast stimulation and collagen synthesis'],
                    ['name' => 'Genomics', 'description' => 'Broad gene expression modulation and transcriptional profiling'],
                ]),
                'key_effects' => json_encode(['Copper ion delivery to cells', 'Collagen and GAG synthesis stimulation', 'Broad gene expression modulation', 'ECM remodeling activation']),
                'common_use_cases' => json_encode(['Wound healing research', 'Dermal fibroblast studies', 'Copper peptide signaling research']),
                'how_it_works' => 'GHK chelates copper(II) ions and delivers them to cells, activating copper-dependent enzymes such as lysyl oxidase for collagen crosslinking. It stimulates fibroblast production of collagen and glycosaminoglycans while modulating metalloproteinase activity for controlled ECM remodeling. Genomic studies indicate modulation of thousands of genes involved in tissue repair, antioxidant response, and inflammation.',
                'rating' => '0.00',
                'rating_count' => 0,
            ],

            // ──────────────────────────────────────────────
            // 2. GHK Basic (Tripeptide-1)
            // ──────────────────────────────────────────────
            'ghk-basic-tripeptide-1' => [
                'title' => 'GHK Basic (Tripeptide-1)',
                'peptide_full_name' => 'Glycyl-L-Histidyl-L-Lysine (Copper-Free Form)',
                'research_title' => 'Tripeptide-1 (GHK): Research Overview of the Copper-Free Cosmetic Peptide',
                'research_outline' => 'An analysis of GHK in its non-copper-complexed form (Tripeptide-1), examining its use in cosmetic research, fibroblast signaling, and collagen stimulation independent of copper delivery.',
                'education_tag' => 'Cosmetic Peptides',
                'description' => 'Tripeptide-1 is the INCI designation for GHK (Gly-His-Lys) in its copper-free form. While structurally identical to GHK, it is studied and formulated without exogenous copper complexation, relying on endogenous copper sources for biological activity. It is widely used in cosmetic research as a signaling peptide for collagen stimulation.',
                'molecular_formula' => 'C₁₄H₂₄N₆O₄',
                'molecular_weight' => '340.38 g/mol',
                'half_life' => 'Variable (dependent on formulation matrix)',
                'bioavailability' => 'Topical penetration enhanced by cosmetic delivery systems',
                'background' => 'Tripeptide-1 is the International Nomenclature of Cosmetic Ingredients (INCI) name for the peptide GHK (glycyl-histidyl-lysine) when used without an exogenous copper complex. In cosmetic science, Tripeptide-1 is classified as a signaling peptide — one that communicates with dermal fibroblasts to promote extracellular matrix production. The rationale for using the copper-free form is that the peptide can bind endogenous copper ions present in the skin, potentially acting as a copper shuttle. Additionally, some formulation chemists prefer the copper-free form for stability and compatibility reasons in complex cosmetic matrices. Tripeptide-1 is among the most extensively studied cosmetic peptides and appears in numerous anti-aging skincare products. In vitro research demonstrates its ability to stimulate collagen synthesis, fibronectin production, and glycosaminoglycan accumulation in dermal fibroblast cultures even without exogenous copper supplementation.',
                'mechanism_of_action_intro' => 'Tripeptide-1 functions as a matrikine — a peptide fragment derived from ECM proteins that signals cells to initiate repair and remodeling processes.',
                'mechanism_subsections' => json_encode([
                    [
                        'intro' => 'As a signaling peptide, Tripeptide-1 interacts with fibroblasts to promote ECM biosynthesis through receptor-mediated and copper-dependent pathways.',
                        'points' => [
                            'Acts as a matrikine signaling molecule, mimicking collagen breakdown fragments that trigger fibroblast activation and new collagen synthesis',
                            'Chelates endogenous copper(II) ions in the skin to form bioactive GHK-Cu in situ',
                            'Stimulates fibroblast production of collagen types I and III, fibronectin, and proteoglycans',
                            'Promotes controlled extracellular matrix turnover through metalloproteinase regulation',
                            'Activates integrin-mediated signaling pathways in dermal fibroblasts',
                        ],
                    ],
                ]),
                'preclinical_intro' => 'Tripeptide-1 has been evaluated in dermal fibroblast cultures, reconstructed skin models, and cosmetic efficacy studies.',
                'preclinical_subsections' => json_encode([
                    [
                        'title' => 'In-Vitro Fibroblast Studies',
                        'findings' => [
                            ['title' => 'Collagen Stimulation', 'description' => 'Human dermal fibroblasts treated with Tripeptide-1 demonstrate increased procollagen I C-terminal peptide (PICP) secretion, indicating enhanced collagen I synthesis. Effects are observed at concentrations as low as 10⁻⁹ M.'],
                            ['title' => 'ECM Protein Production', 'description' => 'In addition to collagen, Tripeptide-1 treatment increases fibronectin and decorin synthesis in fibroblast monolayer cultures, supporting broader ECM remodeling activity.'],
                        ],
                    ],
                    [
                        'title' => 'Reconstructed Skin Models',
                        'findings' => [
                            ['title' => 'Three-Dimensional Tissue Models', 'description' => 'In reconstructed human skin equivalents, Tripeptide-1 application increased epidermal thickness and dermal collagen density compared to untreated controls, suggesting functional ECM enhancement in organotypic culture.'],
                            ['title' => 'Photoaging Models', 'description' => 'UV-irradiated skin models treated with Tripeptide-1 showed reduced MMP-1 expression and preserved collagen architecture relative to UV-exposed controls without peptide treatment.'],
                        ],
                    ],
                ]),
                'preclinical_disclaimer' => 'Findings are from in-vitro cell culture and reconstructed skin model experiments. Results in controlled laboratory settings may not directly predict outcomes in human skin in vivo.',
                'human_use_intro' => 'Tripeptide-1 has been included in cosmetic formulations evaluated in limited observational and supplier-sponsored studies, but no controlled clinical trials for therapeutic endpoints exist.',
                'human_use_subsections' => json_encode([['title' => 'Cosmetic Studies', 'entries' => [['type' => 'content', 'value' => 'Supplier-sponsored studies have reported improvements in skin texture, fine line appearance, and firmness in subjects using Tripeptide-1-containing creams over 8-12 week periods. These studies typically lack independent verification, placebo controls with identical vehicle, or peer-reviewed publication.']]]]),
                'regulatory_subsections' => json_encode([['title' => 'Regulatory Status', 'entries' => [['type' => 'content', 'value' => 'Tripeptide-1 is a recognized cosmetic ingredient (INCI registered) and appears in the EU CosIng database. It is not approved as a drug or therapeutic agent. Research-grade Tripeptide-1 is sold for laboratory research purposes only (RUO).']]]]),
                'regulatory_important_note' => 'Research-grade Tripeptide-1 is sold for in-vitro research purposes only. It is not a cosmetic product, drug, or therapeutic agent.',
                'potential_applications_intro' => 'Based on in-vitro evidence, Tripeptide-1 research is relevant to several areas of skin biology.',
                'potential_applications' => json_encode([
                    ['title' => 'Cosmetic Peptide Research', 'description' => 'Studying signaling peptide mechanisms in fibroblast activation and ECM production.'],
                    ['title' => 'Skin Aging Models', 'description' => 'Investigating matrikine signaling in photoaged and chronologically aged skin cell models.'],
                    ['title' => 'Formulation Science', 'description' => 'Evaluating peptide delivery, stability, and penetration in topical research formulations.'],
                ]),
                'potential_applications_important_context' => 'All applications are based on in-vitro and cosmetic research data. No therapeutic claims are made.',
                'conclusion' => 'Tripeptide-1 represents the copper-free form of the well-characterized GHK peptide, optimized for cosmetic research applications. Its classification as a signaling peptide or matrikine reflects its ability to communicate with dermal fibroblasts and promote extracellular matrix biosynthesis. In-vitro studies consistently demonstrate collagen-stimulatory activity, and its inclusion in commercial skincare products is widespread. However, the distinction between cosmetic ingredient research and therapeutic drug development is important — Tripeptide-1 has not been subjected to the rigorous clinical trial process required for therapeutic claims. Research-grade material serves as a tool for investigating peptide signaling in skin biology, ECM dynamics, and cosmetic formulation science.',
                'references' => json_encode([
                    ['title' => 'International Journal of Cosmetic Science (2009)', 'authors' => 'Maquart FX et al.', 'links' => []],
                    ['title' => 'Journal of Cosmetic Dermatology (2007)', 'authors' => 'Gorouhi F, Maibach HI.', 'links' => []],
                ]),
                'key_points' => json_encode(['Tripeptide-1 is the INCI name for GHK in its copper-free cosmetic form', 'Acts as a matrikine signaling peptide to stimulate fibroblast collagen synthesis', 'Widely studied in cosmetic science for anti-aging skin research', 'Not approved as a therapeutic agent — research use only (RUO)']),
                'overview' => 'Tripeptide-1 (GHK) is a cosmetic signaling peptide that stimulates fibroblast collagen production and ECM remodeling without exogenous copper complexation.',
                'areas_of_research_intro' => 'Tripeptide-1 research spans cosmetic science, dermal cell biology, and formulation development.',
                'areas_of_research' => json_encode([
                    ['name' => 'Cosmetic Science', 'description' => 'Anti-aging peptide efficacy and formulation research'],
                    ['name' => 'Dermal Cell Biology', 'description' => 'Fibroblast signaling and ECM biosynthesis'],
                    ['name' => 'Formulation Research', 'description' => 'Peptide delivery systems and stability studies'],
                ]),
                'key_effects' => json_encode(['Collagen I and III synthesis stimulation', 'Matrikine signaling activity', 'Fibronectin and decorin production', 'ECM remodeling promotion']),
                'common_use_cases' => json_encode(['Cosmetic peptide research', 'Fibroblast signaling studies', 'Anti-aging formulation development']),
                'how_it_works' => 'Tripeptide-1 acts as a matrikine — a peptide derived from ECM protein degradation that signals fibroblasts to initiate repair. It stimulates collagen I and III synthesis, fibronectin production, and glycosaminoglycan accumulation. In the skin, it can chelate endogenous copper to form the bioactive GHK-Cu complex in situ.',
                'rating' => '0.00',
                'rating_count' => 0,
            ],

            // ──────────────────────────────────────────────
            // 3. Pal-GHK
            // ──────────────────────────────────────────────
            'pal-ghk' => [
                'title' => 'Pal-GHK',
                'peptide_full_name' => 'Palmitoyl Tripeptide-1 (Palmitoyl-Glycyl-Histidyl-Lysine)',
                'research_title' => 'Pal-GHK (Palmitoyl Tripeptide-1): A Comprehensive Research Overview',
                'research_outline' => 'An analysis of Pal-GHK, a lipid-modified form of the GHK tripeptide engineered for enhanced skin penetration, examining its collagen-stimulatory effects, matrikine signaling, and role in cosmetic peptide research.',
                'education_tag' => 'Cosmetic Peptides',
                'description' => 'Pal-GHK (Palmitoyl Tripeptide-1) is a lipopeptide derivative of GHK created by conjugating a palmitic acid (C16) chain to the N-terminus. This lipid modification dramatically enhances skin penetration and cellular uptake while preserving the collagen-stimulatory signaling properties of the parent GHK peptide.',
                'molecular_formula' => 'C₃₀H₅₆N₆O₅',
                'molecular_weight' => '578.81 g/mol',
                'half_life' => 'Extended relative to GHK due to lipid conjugation (specific data limited)',
                'bioavailability' => 'Enhanced topical penetration due to palmitoyl moiety',
                'background' => 'Pal-GHK (Palmitoyl Tripeptide-1) was developed to overcome the primary limitation of the native GHK tripeptide in topical applications: poor penetration through the stratum corneum. By conjugating a 16-carbon palmitic acid chain to the N-terminal glycine, researchers created a lipophilic derivative capable of traversing the lipid-rich intercellular matrix of the skin barrier. Once internalized, cellular esterases cleave the palmitoyl group, liberating the active GHK peptide intracellularly. This prodrug approach is common in cosmetic peptide chemistry. Pal-GHK retains the matrikine signaling properties of GHK and has been shown to stimulate collagen synthesis in dermal fibroblast cultures with enhanced potency relative to the unmodified tripeptide, likely due to improved cellular uptake. It is frequently combined with Palmitoyl Tetrapeptide-7 in commercial formulations (marketed as Matrixyl 3000).',
                'mechanism_of_action_intro' => 'Pal-GHK functions as a lipophilic prodrug that delivers the active GHK tripeptide to dermal cells, where it activates matrikine signaling and collagen biosynthesis pathways.',
                'mechanism_subsections' => json_encode([
                    [
                        'intro' => 'The palmitoyl conjugation enhances delivery while the released GHK peptide drives the biological signaling response.',
                        'points' => [
                            'Palmitoyl chain enables passage through the stratum corneum lipid matrix, dramatically improving topical bioavailability',
                            'Intracellular esterases cleave the palmitoyl group, releasing active GHK for receptor engagement and copper chelation',
                            'Activates fibroblast TGF-β signaling pathway, promoting procollagen I and III transcription',
                            'Stimulates tissue inhibitor of metalloproteinases (TIMP) expression, favoring net collagen accumulation',
                            'Released GHK can chelate endogenous copper for lysyl oxidase activation and collagen crosslinking',
                        ],
                    ],
                ]),
                'preclinical_intro' => 'Pal-GHK has been evaluated in fibroblast cultures, skin penetration studies, and reconstructed tissue models.',
                'preclinical_subsections' => json_encode([
                    [
                        'title' => 'Penetration and Delivery Studies',
                        'findings' => [
                            ['title' => 'Skin Permeation', 'description' => 'Franz diffusion cell experiments using human skin samples demonstrate that palmitoylation increases GHK permeation across the stratum corneum by approximately 4-8 fold compared to the unmodified tripeptide.'],
                            ['title' => 'Cellular Uptake', 'description' => 'Fluorescently labeled Pal-GHK shows significantly enhanced fibroblast uptake in confocal microscopy studies compared to unmodified GHK, with preferential membrane association consistent with the lipophilic modification.'],
                        ],
                    ],
                    [
                        'title' => 'Collagen and ECM Studies',
                        'findings' => [
                            ['title' => 'Procollagen Synthesis', 'description' => 'In cultured human dermal fibroblasts, Pal-GHK at 10⁻⁶ M stimulated procollagen I synthesis by approximately 100-150% over untreated controls, with greater potency than equimolar unmodified GHK.'],
                            ['title' => 'Combination with Palmitoyl Tetrapeptide-7', 'description' => 'The combination of Pal-GHK with Palmitoyl Tetrapeptide-7 (Matrixyl 3000) demonstrated synergistic effects on collagen production and anti-inflammatory IL-6 suppression in fibroblast and keratinocyte co-culture systems.'],
                        ],
                    ],
                ]),
                'preclinical_disclaimer' => 'All findings are from in-vitro cell culture and skin model experiments. Results may not directly predict in-vivo human outcomes.',
                'human_use_intro' => 'No controlled clinical trials have evaluated Pal-GHK as a standalone therapeutic. Cosmetic efficacy studies of formulations containing Pal-GHK have been published, primarily by ingredient suppliers.',
                'human_use_subsections' => json_encode([['title' => 'Cosmetic Studies', 'entries' => [['type' => 'content', 'value' => 'Supplier-sponsored studies of Matrixyl 3000 (Pal-GHK + Palmitoyl Tetrapeptide-7) reported reductions in wrinkle depth and improvements in skin firmness in subjects over 8-12 weeks. These studies have methodological limitations including lack of independent verification.']]]]),
                'regulatory_subsections' => json_encode([['title' => 'Regulatory Status', 'entries' => [['type' => 'content', 'value' => 'Palmitoyl Tripeptide-1 is a recognized cosmetic ingredient (INCI registered). It is not approved as a drug or therapeutic agent. Research-grade Pal-GHK is sold for laboratory research purposes only (RUO).']]]]),
                'regulatory_important_note' => 'Research-grade Pal-GHK is sold for in-vitro research purposes only. It is not a finished cosmetic product or therapeutic agent.',
                'potential_applications_intro' => 'Pal-GHK research is relevant to cosmetic peptide science, delivery systems, and skin biology.',
                'potential_applications' => json_encode([
                    ['title' => 'Lipopeptide Delivery Research', 'description' => 'Studying palmitoylation as a strategy for enhancing peptide penetration in topical research formulations.'],
                    ['title' => 'ECM Remodeling Studies', 'description' => 'Investigating fibroblast collagen synthesis stimulation by matrikine signaling peptides.'],
                    ['title' => 'Combination Peptide Research', 'description' => 'Evaluating synergistic effects of multi-peptide systems on skin cell biology.'],
                ]),
                'potential_applications_important_context' => 'All applications are based on in-vitro research. No therapeutic claims are made.',
                'conclusion' => 'Pal-GHK represents a rational lipopeptide engineering approach to overcoming the topical delivery limitations of the well-characterized GHK tripeptide. The palmitoyl conjugation strategy — now widely adopted across cosmetic peptide chemistry — provides enhanced stratum corneum penetration while preserving the matrikine signaling activity of the parent peptide. In-vitro evidence supports its collagen-stimulatory effects, and its commercial success in formulations such as Matrixyl 3000 reflects industry confidence in the approach. However, the gap between in-vitro fibroblast assays and rigorous clinical proof of efficacy remains, and research-grade Pal-GHK is strictly a laboratory tool for investigating lipopeptide delivery and skin cell signaling.',
                'references' => json_encode([
                    ['title' => 'International Journal of Cosmetic Science (2005)', 'authors' => 'Robinson LR et al.', 'links' => []],
                    ['title' => 'Experimental Dermatology (2003)', 'authors' => 'Lintner K, Peschard O.', 'links' => []],
                ]),
                'key_points' => json_encode(['Pal-GHK is a palmitoylated derivative of GHK designed for enhanced skin penetration', 'The palmitoyl group is cleaved intracellularly to release active GHK', 'Stimulates collagen synthesis with greater potency than unmodified GHK in vitro', 'Not approved for therapeutic use — research use only (RUO)']),
                'overview' => 'Pal-GHK is a lipid-modified tripeptide that enhances skin penetration and collagen stimulation through palmitoyl-conjugated matrikine signaling.',
                'areas_of_research_intro' => 'Pal-GHK research spans lipopeptide delivery science, dermal cell biology, and cosmetic formulation.',
                'areas_of_research' => json_encode([
                    ['name' => 'Lipopeptide Delivery', 'description' => 'Palmitoylation-enhanced skin penetration and cellular uptake'],
                    ['name' => 'ECM Biology', 'description' => 'Collagen synthesis stimulation and matrix remodeling'],
                    ['name' => 'Cosmetic Science', 'description' => 'Anti-aging peptide formulation and efficacy research'],
                ]),
                'key_effects' => json_encode(['Enhanced skin penetration vs native GHK', 'Collagen I and III synthesis stimulation', 'Matrikine signaling activation', 'Prodrug release of active GHK']),
                'common_use_cases' => json_encode(['Topical peptide delivery research', 'Fibroblast collagen studies', 'Cosmetic peptide formulation research']),
                'how_it_works' => 'The palmitoyl chain on Pal-GHK enables passage through the lipid-rich stratum corneum. Once internalized by skin cells, esterases cleave the palmitoyl group, releasing active GHK. The freed peptide activates matrikine signaling in fibroblasts, stimulating TGF-β-mediated procollagen transcription and promoting ECM biosynthesis.',
                'rating' => '0.00',
                'rating_count' => 0,
            ],

            // ──────────────────────────────────────────────
            // 4. Pal-AHK
            // ──────────────────────────────────────────────
            'pal-ahk' => [
                'title' => 'Pal-AHK',
                'peptide_full_name' => 'Palmitoyl Alanyl-Histidyl-Lysine',
                'research_title' => 'Pal-AHK: A Comprehensive Research Overview of the Copper Peptide Analog',
                'research_outline' => 'An analysis of Pal-AHK, a palmitoylated copper peptide analog with relevance to hair follicle and skin biology research, examining its structural relationship to GHK and its unique biological profile.',
                'education_tag' => 'Copper Peptides',
                'description' => 'Pal-AHK (Palmitoyl Ala-His-Lys) is a lipid-modified tripeptide analog of GHK in which the N-terminal glycine is replaced with alanine. Like GHK, it possesses copper(II) binding capacity through its His-Lys motif. The palmitoyl conjugation enhances lipophilicity for improved skin and scalp penetration in topical research applications.',
                'molecular_formula' => 'C₃₁H₅₈N₆O₅',
                'molecular_weight' => '592.84 g/mol',
                'half_life' => 'Extended relative to unmodified AHK (specific data limited)',
                'bioavailability' => 'Enhanced topical penetration via palmitoyl modification',
                'background' => 'Pal-AHK is a synthetic lipopeptide that represents a structural analog of the well-known copper-binding peptide GHK. In this analog, the glycine residue at position 1 is replaced with alanine, creating the Ala-His-Lys (AHK) sequence. The histidine-lysine motif responsible for copper(II) coordination is preserved, maintaining the peptide\'s ability to form copper complexes. The addition of a palmitoyl chain to the N-terminal alanine enhances lipophilicity and skin penetration capacity. Pal-AHK has attracted particular research interest in the context of hair follicle biology, where copper peptides have been studied for their effects on dermal papilla cells and hair growth cycle regulation. The peptide has also been investigated in the broader context of skin ECM remodeling, where copper delivery to lysyl oxidase and other copper-dependent enzymes plays a role in collagen crosslinking and tissue integrity.',
                'mechanism_of_action_intro' => 'Pal-AHK acts as a lipophilic copper-binding peptide that delivers bioavailable copper to skin and follicular cells while activating ECM biosynthesis pathways.',
                'mechanism_subsections' => json_encode([
                    [
                        'intro' => 'The mechanism involves both copper-dependent enzymatic activation and direct peptide signaling through matrikine-like pathways.',
                        'points' => [
                            'Chelates copper(II) through the conserved His-Lys binding motif, delivering bioavailable copper to dermal and follicular cells',
                            'Palmitoyl chain facilitates penetration through the stratum corneum and follicular epithelium',
                            'Activates copper-dependent enzymes including lysyl oxidase (collagen crosslinking) and superoxide dismutase (antioxidant defense)',
                            'Stimulates dermal papilla cell proliferation and expression of hair growth-related genes in vitro',
                            'Promotes VEGF expression in cultured scalp cells, potentially supporting follicular vascularization',
                        ],
                    ],
                ]),
                'preclinical_intro' => 'Pal-AHK has been studied in dermal fibroblast and dermal papilla cell cultures, with a particular focus on hair follicle biology.',
                'preclinical_subsections' => json_encode([
                    [
                        'title' => 'Hair Follicle Research',
                        'findings' => [
                            ['title' => 'Dermal Papilla Cell Stimulation', 'description' => 'In cultured human dermal papilla cells, AHK-Cu treatment increased cell proliferation markers and upregulated expression of growth factors associated with the anagen (growth) phase of the hair cycle, including VEGF and IGF-1.'],
                            ['title' => 'Follicular Penetration', 'description' => 'The palmitoyl modification enhances penetration through the follicular route, which is particularly relevant for targeting the dermal papilla and hair bulge regions of the follicle.'],
                        ],
                    ],
                    [
                        'title' => 'Skin ECM Studies',
                        'findings' => [
                            ['title' => 'Collagen Production', 'description' => 'In human dermal fibroblast cultures, Pal-AHK stimulated procollagen synthesis, though with slightly different potency and kinetics compared to equimolar Pal-GHK, suggesting the alanine substitution modestly alters receptor interactions.'],
                            ['title' => 'Antioxidant Activity', 'description' => 'Copper delivery by AHK supports superoxide dismutase activity in cell cultures, contributing to antioxidant defense in oxidatively stressed skin cell models.'],
                        ],
                    ],
                ]),
                'preclinical_disclaimer' => 'All findings are from in-vitro cell culture experiments. No controlled human clinical trials have been published for Pal-AHK.',
                'human_use_intro' => 'No controlled clinical trials evaluating Pal-AHK have been published. It appears in some cosmetic hair care formulations, but clinical efficacy data is limited to supplier-sponsored assessments.',
                'human_use_subsections' => json_encode([['title' => 'Clinical Evidence', 'entries' => [['type' => 'content', 'value' => 'Pal-AHK has not been evaluated in peer-reviewed human clinical trials. Supplier assessments report improvements in hair density measurements in small observational panels, but these lack the methodological rigor required for definitive conclusions.']]]]),
                'regulatory_subsections' => json_encode([['title' => 'Regulatory Status', 'entries' => [['type' => 'content', 'value' => 'Pal-AHK is used as a cosmetic ingredient in hair care formulations. It is not approved by the FDA or EMA as a therapeutic agent. Research-grade Pal-AHK is sold for laboratory research purposes only (RUO).']]]]),
                'regulatory_important_note' => 'Research-grade Pal-AHK is sold for in-vitro research purposes only. It is not approved for therapeutic use.',
                'potential_applications_intro' => 'Preclinical data supports research applications in hair biology and copper peptide signaling.',
                'potential_applications' => json_encode([
                    ['title' => 'Hair Follicle Biology', 'description' => 'Studying copper peptide effects on dermal papilla cells and hair cycle regulation.'],
                    ['title' => 'Copper Delivery Research', 'description' => 'Investigating lipopeptide copper chelates as delivery systems for copper-dependent enzymatic processes.'],
                ]),
                'potential_applications_important_context' => 'All applications are based on in-vitro research. No therapeutic claims are made.',
                'conclusion' => 'Pal-AHK is a rationally designed copper peptide analog that combines the copper-binding capacity of the AHK motif with enhanced tissue penetration from palmitoyl conjugation. Its particular relevance to hair follicle research — through dermal papilla cell stimulation and follicular delivery — distinguishes it from other copper peptides in the cosmetic research space. While in-vitro data supports its biological activity, the absence of rigorous clinical trials limits conclusions about translational potential. Pal-AHK remains a research tool for investigating copper peptide signaling in skin and follicular biology.',
                'references' => json_encode([
                    ['title' => 'Journal of Cosmetic Science (2012)', 'authors' => 'Pyo HK et al.', 'links' => []],
                    ['title' => 'Skin Pharmacology and Physiology (2015)', 'authors' => 'Kang YA et al.', 'links' => []],
                ]),
                'key_points' => json_encode(['Pal-AHK is a palmitoylated copper-binding tripeptide analog of GHK', 'Alanine substitution at position 1 preserves copper-binding through the His-Lys motif', 'Studied primarily for dermal papilla cell stimulation in hair biology research', 'Not approved for therapeutic use — research use only (RUO)']),
                'overview' => 'Pal-AHK is a lipid-modified copper peptide analog studied for its effects on hair follicle biology and skin ECM remodeling.',
                'areas_of_research_intro' => 'Pal-AHK research focuses on hair biology, copper peptide signaling, and lipopeptide delivery.',
                'areas_of_research' => json_encode([
                    ['name' => 'Hair Biology', 'description' => 'Dermal papilla stimulation and hair cycle regulation'],
                    ['name' => 'Copper Peptide Research', 'description' => 'Copper delivery and enzyme activation in skin cells'],
                    ['name' => 'Cosmetic Science', 'description' => 'Scalp care peptide formulation and delivery'],
                ]),
                'key_effects' => json_encode(['Copper(II) chelation and delivery', 'Dermal papilla cell stimulation', 'Enhanced follicular penetration', 'Collagen crosslinking support']),
                'common_use_cases' => json_encode(['Hair follicle biology research', 'Copper peptide signaling studies', 'Scalp penetration research']),
                'how_it_works' => 'Pal-AHK penetrates the skin and follicular epithelium via its palmitoyl chain. The His-Lys motif chelates copper(II) ions, delivering them to cells for activation of copper-dependent enzymes including lysyl oxidase and superoxide dismutase. In dermal papilla cells, it promotes proliferation and expression of anagen-associated growth factors.',
                'rating' => '0.00',
                'rating_count' => 0,
            ],

            // ──────────────────────────────────────────────
            // 5. AHK-Cu
            // ──────────────────────────────────────────────
            'ahk-cu' => [
                'title' => 'AHK-Cu',
                'peptide_full_name' => 'Copper Complex of Alanyl-Histidyl-Lysine',
                'research_title' => 'AHK-Cu: A Comprehensive Research Overview of the Copper Tripeptide Complex',
                'research_outline' => 'An analysis of AHK-Cu, a copper complex of the tripeptide Ala-His-Lys, examining its role in hair follicle research, dermal papilla cell biology, and copper-dependent tissue remodeling.',
                'education_tag' => 'Copper Peptides',
                'description' => 'AHK-Cu is the copper(II) complex of the tripeptide alanyl-histidyl-lysine (Ala-His-Lys). Structurally analogous to GHK-Cu, it delivers bioavailable copper to cells through the conserved histidine-lysine coordination motif. Research interest centers on its effects on hair follicle dermal papilla cells and its role in stimulating growth factor expression relevant to the hair cycle.',
                'molecular_formula' => 'C₁₅H₂₆CuN₆O₄',
                'molecular_weight' => '417.95 g/mol',
                'half_life' => 'Minutes to hours (typical for small copper peptide complexes)',
                'bioavailability' => 'Dependent on formulation and delivery system in research settings',
                'background' => 'AHK-Cu is a copper(II) tripeptide complex formed between the synthetic peptide Ala-His-Lys and a copper ion. It belongs to the family of copper-binding peptides that share the ATCUN (amino terminal copper and nickel) binding motif, characterized by a histidine at position 3 coordinating metal ions alongside the terminal amine and intervening amide nitrogens. While GHK-Cu has received the most research attention in this family, AHK-Cu has emerged as a compound of particular interest in hair biology research. Studies in dermal papilla cells — the specialized mesenchymal cells that govern hair follicle cycling — have shown that AHK-Cu stimulates proliferation and upregulates key signaling molecules associated with the anagen (growth) phase. The compound has also been evaluated for broader skin remodeling effects, drawing on the established role of copper ions in lysyl oxidase activity, antioxidant enzyme function, and angiogenic signaling.',
                'mechanism_of_action_intro' => 'AHK-Cu functions as a copper delivery complex that activates copper-dependent enzymes and stimulates growth factor signaling in dermal and follicular cells.',
                'mechanism_subsections' => json_encode([
                    [
                        'intro' => 'The biological effects of AHK-Cu arise from both copper delivery to intracellular enzymes and direct peptide-mediated signaling pathways.',
                        'points' => [
                            'Delivers copper(II) to dermal papilla cells, activating copper-dependent enzymes involved in ECM maturation and antioxidant defense',
                            'Stimulates VEGF (vascular endothelial growth factor) expression in dermal papilla cells, supporting perifollicular vascularization',
                            'Upregulates Wnt/β-catenin pathway signaling components associated with hair follicle neogenesis and anagen induction',
                            'Promotes proliferation of dermal papilla cells in culture, counteracting the growth arrest associated with balding-derived cells',
                            'Activates lysyl oxidase for collagen and elastin crosslinking in the perifollicular connective tissue sheath',
                        ],
                    ],
                ]),
                'preclinical_intro' => 'AHK-Cu has been studied primarily in dermal papilla cell culture systems and in comparative analyses with other copper peptide complexes.',
                'preclinical_subsections' => json_encode([
                    [
                        'title' => 'Hair Follicle Biology',
                        'findings' => [
                            ['title' => 'Dermal Papilla Proliferation', 'description' => 'In cultured human dermal papilla cells, AHK-Cu treatment (1-10 μM) increased cell proliferation as measured by MTT assays, with effects comparable to or exceeding those of GHK-Cu at equivalent concentrations.'],
                            ['title' => 'Growth Factor Expression', 'description' => 'qRT-PCR analysis of AHK-Cu-treated dermal papilla cells showed upregulation of VEGF, KGF (keratinocyte growth factor), and other anagen-associated transcripts, suggesting activation of hair growth-promoting signaling pathways.'],
                        ],
                    ],
                    [
                        'title' => 'Copper-Dependent Enzyme Studies',
                        'findings' => [
                            ['title' => 'Lysyl Oxidase Activity', 'description' => 'AHK-Cu serves as a copper source for lysyl oxidase in fibroblast cultures, supporting collagen and elastin crosslinking in ECM maturation assays.'],
                            ['title' => 'SOD Activity', 'description' => 'Copper delivered by AHK-Cu supports copper-zinc superoxide dismutase (Cu/Zn-SOD) activity in cell extracts, contributing to antioxidant defense mechanisms.'],
                        ],
                    ],
                ]),
                'preclinical_disclaimer' => 'All findings are from in-vitro cell culture experiments. No controlled human clinical trials have been published for AHK-Cu.',
                'human_use_intro' => 'No peer-reviewed human clinical trials evaluating AHK-Cu have been published.',
                'human_use_subsections' => json_encode([['title' => 'Clinical Evidence', 'entries' => [['type' => 'content', 'value' => 'AHK-Cu has not undergone formal clinical evaluation. Its inclusion in some hair care products is based on in-vitro data rather than controlled clinical efficacy trials.']]]]),
                'regulatory_subsections' => json_encode([['title' => 'Regulatory Status', 'entries' => [['type' => 'content', 'value' => 'AHK-Cu is not approved by the FDA or EMA as a drug or therapeutic agent. It appears in some cosmetic hair care ingredients but is not classified as a pharmaceutical. Research-grade AHK-Cu is sold for laboratory research purposes only (RUO).']]]]),
                'regulatory_important_note' => 'Research-grade AHK-Cu is sold for in-vitro research purposes only. It is not approved for therapeutic use or self-administration.',
                'potential_applications_intro' => 'In-vitro data supports research applications in follicular biology and copper-dependent cell signaling.',
                'potential_applications' => json_encode([
                    ['title' => 'Hair Cycle Research', 'description' => 'Studying copper peptide effects on dermal papilla cell signaling and anagen induction mechanisms.'],
                    ['title' => 'Copper Biology', 'description' => 'Investigating copper delivery to follicular and dermal cells for enzyme activation studies.'],
                ]),
                'potential_applications_important_context' => 'All applications are based on in-vitro research. No therapeutic claims are made.',
                'conclusion' => 'AHK-Cu is a copper tripeptide complex with a growing body of in-vitro evidence supporting its role in hair follicle biology research. Its ability to stimulate dermal papilla cell proliferation and upregulate anagen-associated growth factors positions it as a relevant research tool for studying copper-dependent signaling in follicular cells. While structurally related to the more extensively characterized GHK-Cu, AHK-Cu appears to have a distinct biological profile in dermal papilla assays. The absence of clinical trial data limits translational conclusions, and research-grade AHK-Cu remains an investigational laboratory tool.',
                'references' => json_encode([
                    ['title' => 'Annals of Dermatology (2007)', 'authors' => 'Pyo HK et al.', 'links' => []],
                    ['title' => 'Journal of Investigative Dermatology (2004)', 'authors' => 'Kang YA et al.', 'links' => []],
                ]),
                'key_points' => json_encode(['AHK-Cu is a copper(II) complex of the tripeptide Ala-His-Lys', 'Stimulates dermal papilla cell proliferation and VEGF expression in vitro', 'Delivers bioavailable copper for lysyl oxidase and SOD activation', 'Not approved for therapeutic use — research use only (RUO)']),
                'overview' => 'AHK-Cu is a copper tripeptide complex studied for its stimulatory effects on dermal papilla cells and hair follicle biology.',
                'areas_of_research_intro' => 'AHK-Cu research focuses on hair follicle biology, copper enzyme activation, and dermal cell signaling.',
                'areas_of_research' => json_encode([
                    ['name' => 'Hair Follicle Biology', 'description' => 'Dermal papilla proliferation and anagen signaling'],
                    ['name' => 'Copper Biochemistry', 'description' => 'Copper delivery and metalloenzyme activation'],
                ]),
                'key_effects' => json_encode(['Dermal papilla cell proliferation', 'VEGF and growth factor upregulation', 'Copper-dependent enzyme activation', 'ECM crosslinking support']),
                'common_use_cases' => json_encode(['Hair biology research', 'Copper peptide signaling studies', 'Dermal papilla cell culture experiments']),
                'how_it_works' => 'AHK-Cu delivers copper(II) to dermal papilla and fibroblast cells through the conserved His-Lys coordination motif. Intracellular copper release activates lysyl oxidase for ECM crosslinking and Cu/Zn-SOD for antioxidant defense. In dermal papilla cells, it stimulates VEGF expression and Wnt/β-catenin signaling associated with anagen phase induction.',
                'rating' => '0.00',
                'rating_count' => 0,
            ],

            // ──────────────────────────────────────────────
            // 6. Matrixyl (Palmitoyl Pentapeptide-4)
            // ──────────────────────────────────────────────
            'matrixyl' => [
                'title' => 'Matrixyl (Palmitoyl Pentapeptide-4)',
                'peptide_full_name' => 'Palmitoyl-Lys-Thr-Thr-Lys-Ser (Pal-KTTKS)',
                'research_title' => 'Matrixyl (Pal-KTTKS): A Comprehensive Research Overview',
                'research_outline' => 'An analysis of Matrixyl (Palmitoyl Pentapeptide-4), the flagship cosmetic peptide derived from the KTTKS collagen fragment, examining its matrikine signaling, collagen stimulation, and pivotal role in cosmetic peptide research.',
                'education_tag' => 'Cosmetic Peptides',
                'description' => 'Matrixyl is the trade name for Palmitoyl Pentapeptide-4 (Pal-KTTKS), a lipopeptide derived from the pro-collagen I C-terminal propeptide sequence KTTKS. This pentapeptide fragment was identified as the minimal active sequence capable of stimulating new collagen synthesis in dermal fibroblasts, functioning as a matrikine signaling molecule.',
                'molecular_formula' => 'C₃₂H₅₇N₅O₉',
                'molecular_weight' => '802.14 g/mol (as palmitoyl pentapeptide-4)',
                'half_life' => 'Extended relative to KTTKS due to palmitoyl conjugation',
                'bioavailability' => 'Enhanced topical penetration via palmitoyl moiety',
                'background' => 'Matrixyl (Palmitoyl Pentapeptide-4, Pal-KTTKS) is one of the most extensively studied and commercially successful cosmetic peptides. It was developed by Sederma (now part of Croda International) based on the discovery that the pentapeptide sequence KTTKS (Lys-Thr-Thr-Lys-Ser), derived from the C-terminal propeptide of type I procollagen, acts as a potent matrikine — a matrix-derived peptide that signals fibroblasts to produce new extracellular matrix components. The original research by Katayama et al. demonstrated that KTTKS stimulated collagen I, collagen III, and fibronectin synthesis in cultured fibroblasts. The palmitoyl modification was subsequently added to enhance skin penetration by increasing lipophilicity. Matrixyl became a benchmark compound in cosmetic peptide science and paved the way for subsequent matrikine peptide development. It is included in thousands of commercial skincare products worldwide and has been the subject of multiple published studies.',
                'mechanism_of_action_intro' => 'Matrixyl functions as a matrikine — specifically, as a fragment of collagen I that mimics the signaling properties of collagen degradation products, stimulating fibroblasts to produce new ECM.',
                'mechanism_subsections' => json_encode([
                    [
                        'intro' => 'The KTTKS sequence triggers a positive feedback loop in collagen biosynthesis, effectively telling fibroblasts that matrix degradation has occurred and new synthesis is needed.',
                        'points' => [
                            'KTTKS mimics type I procollagen C-terminal propeptide fragments released during collagen turnover, activating fibroblast ECM biosynthesis programs',
                            'Stimulates TGF-β signaling pathway, the master regulator of collagen gene transcription in dermal fibroblasts',
                            'Increases transcription and secretion of procollagen I, procollagen III, and fibronectin',
                            'Palmitoyl moiety enables stratum corneum penetration; intracellular esterases release the active KTTKS peptide',
                            'Promotes hyaluronic acid synthase expression, contributing to dermal hydration and volume in tissue models',
                        ],
                    ],
                ]),
                'preclinical_intro' => 'Matrixyl has one of the most extensive in-vitro evidence bases of any cosmetic peptide, with studies spanning fibroblast cultures, skin equivalents, and comparative peptide analyses.',
                'preclinical_subsections' => json_encode([
                    [
                        'title' => 'Fibroblast and ECM Studies',
                        'findings' => [
                            ['title' => 'Collagen Synthesis', 'description' => 'The foundational study by Katayama et al. demonstrated that KTTKS at micromolar concentrations stimulated type I collagen synthesis in human fibroblast cultures by up to 150-200% over controls. Subsequent studies confirmed dose-dependent stimulation of types I and III collagen, fibronectin, and elastin.'],
                            ['title' => 'ECM Protein Profiling', 'description' => 'Proteomic analysis of Pal-KTTKS-treated fibroblast cultures revealed upregulation of multiple ECM components beyond collagen, including fibrillin, proteoglycans, and basement membrane proteins, suggesting broad matrikine signaling activity.'],
                        ],
                    ],
                    [
                        'title' => 'Skin Model Studies',
                        'findings' => [
                            ['title' => 'Reconstructed Skin Equivalents', 'description' => 'In three-dimensional skin models, Pal-KTTKS application increased dermal collagen density and epidermal thickness as measured by histological analysis, supporting functional ECM enhancement in organotypic culture.'],
                            ['title' => 'Photoaging Models', 'description' => 'UV-irradiated skin equivalents treated with Pal-KTTKS showed preserved collagen architecture and reduced MMP-1 induction compared to irradiated untreated controls.'],
                        ],
                    ],
                ]),
                'preclinical_disclaimer' => 'In-vitro and skin model findings may not directly predict outcomes in human skin in vivo. Cosmetic efficacy and therapeutic efficacy are distinct regulatory categories.',
                'human_use_intro' => 'Matrixyl has been evaluated in several small-scale human studies, primarily sponsored by ingredient suppliers, making it one of the better-studied cosmetic peptides at the clinical level.',
                'human_use_subsections' => json_encode([['title' => 'Cosmetic Efficacy Studies', 'entries' => [['type' => 'content', 'value' => 'Supplier-sponsored studies reported statistically significant reductions in wrinkle surface area and depth following 4-8 weeks of topical Pal-KTTKS application in human volunteers. One published study using optical profilometry reported wrinkle reduction effects. However, these studies generally lack the methodological rigor of pharmaceutical trials.']]]]),
                'regulatory_subsections' => json_encode([['title' => 'Regulatory Status', 'entries' => [['type' => 'content', 'value' => 'Palmitoyl Pentapeptide-4 is a registered cosmetic ingredient (INCI) included in the EU CosIng database. It is not approved as a drug or therapeutic agent. Research-grade Matrixyl is sold for laboratory research purposes only (RUO).']]]]),
                'regulatory_important_note' => 'Research-grade Matrixyl (Pal-KTTKS) is sold for in-vitro research purposes only. It is not a cosmetic product or therapeutic agent.',
                'potential_applications_intro' => 'Matrixyl remains a reference compound in cosmetic peptide research with broad applications in skin biology.',
                'potential_applications' => json_encode([
                    ['title' => 'Matrikine Signaling Research', 'description' => 'Studying the mechanism by which collagen-derived fragments stimulate new ECM biosynthesis in fibroblasts.'],
                    ['title' => 'Cosmetic Peptide Benchmarking', 'description' => 'As one of the most characterized cosmetic peptides, Matrixyl serves as a reference standard for evaluating new peptide candidates.'],
                    ['title' => 'Skin Aging Models', 'description' => 'Investigating collagen homeostasis and ECM dynamics in chronological and photoaging research.'],
                ]),
                'potential_applications_important_context' => 'All applications are based on in-vitro and cosmetic research. No therapeutic claims are made.',
                'conclusion' => 'Matrixyl (Palmitoyl Pentapeptide-4) represents a landmark achievement in cosmetic peptide science. The identification of KTTKS as the minimal collagen-derived matrikine sequence, combined with the palmitoyl delivery strategy, established the paradigm for an entire class of cosmetic active ingredients. Its extensive in-vitro evidence base, combined with limited but suggestive human cosmetic studies, has made it the reference standard in the field. However, the distinction between cosmetic efficacy claims and pharmaceutical therapeutic proof remains important — Matrixyl has not undergone the rigorous clinical trial process required for drug approval. Research-grade Pal-KTTKS continues to serve as a valuable tool for investigating matrikine signaling, collagen homeostasis, and skin cell biology.',
                'references' => json_encode([
                    ['title' => 'Journal of Biological Chemistry (1993)', 'authors' => 'Katayama K et al.', 'links' => []],
                    ['title' => 'International Journal of Cosmetic Science (2005)', 'authors' => 'Robinson LR et al.', 'links' => []],
                    ['title' => 'Experimental Dermatology (2003)', 'authors' => 'Lintner K, Peschard O.', 'links' => []],
                ]),
                'key_points' => json_encode(['Matrixyl (Pal-KTTKS) is the most widely studied matrikine cosmetic peptide', 'KTTKS sequence derived from type I procollagen C-terminal propeptide', 'Stimulates collagen I, III, fibronectin, and broader ECM production in fibroblasts', 'Not approved as a therapeutic agent — research use only (RUO)']),
                'overview' => 'Matrixyl is a palmitoylated pentapeptide (Pal-KTTKS) that acts as a collagen-derived matrikine, stimulating fibroblast ECM production in cosmetic research.',
                'areas_of_research_intro' => 'Matrixyl research spans matrikine biology, cosmetic science, and dermal cell signaling.',
                'areas_of_research' => json_encode([
                    ['name' => 'Matrikine Biology', 'description' => 'Collagen fragment signaling and ECM feedback mechanisms'],
                    ['name' => 'Cosmetic Science', 'description' => 'Anti-aging peptide formulation and efficacy benchmarking'],
                    ['name' => 'Dermal Cell Biology', 'description' => 'Fibroblast activation, collagen synthesis, and matrix dynamics'],
                ]),
                'key_effects' => json_encode(['Collagen I and III synthesis stimulation', 'Fibronectin and ECM protein upregulation', 'Matrikine signaling activation', 'TGF-β pathway engagement']),
                'common_use_cases' => json_encode(['Collagen signaling research', 'Cosmetic peptide benchmarking', 'Anti-aging formulation studies']),
                'how_it_works' => 'The KTTKS sequence mimics collagen I degradation fragments that signal fibroblasts through TGF-β-mediated pathways to synthesize new ECM. The palmitoyl chain enables stratum corneum penetration, and intracellular esterases release the active pentapeptide. This triggers upregulation of procollagen I, procollagen III, fibronectin, and other matrix proteins.',
                'rating' => '0.00',
                'rating_count' => 0,
            ],

            // ──────────────────────────────────────────────
            // 7. Palmitoyl Tetrapeptide-7
            // ──────────────────────────────────────────────
            'palmitoyl-tetrapeptide-7' => [
                'title' => 'Palmitoyl Tetrapeptide-7',
                'peptide_full_name' => 'Palmitoyl-Gly-Gln-Pro-Arg',
                'research_title' => 'Palmitoyl Tetrapeptide-7: A Comprehensive Research Overview',
                'research_outline' => 'An analysis of Palmitoyl Tetrapeptide-7, an anti-inflammatory cosmetic peptide studied for its ability to modulate IL-6 secretion and complement activation in skin cell models.',
                'education_tag' => 'Cosmetic Peptides',
                'description' => 'Palmitoyl Tetrapeptide-7 (formerly Palmitoyl Tetrapeptide-3) is a lipid-modified tetrapeptide (Pal-GQPR) studied for its anti-inflammatory properties in skin biology. Research focuses on its ability to suppress interleukin-6 (IL-6) secretion and inhibit complement-mediated inflammatory responses in keratinocyte and fibroblast cultures.',
                'molecular_formula' => 'C₃₀H₅₅N₇O₇',
                'molecular_weight' => '629.80 g/mol',
                'half_life' => 'Extended relative to unmodified peptide (specific data limited)',
                'bioavailability' => 'Enhanced topical penetration via palmitoyl modification',
                'background' => 'Palmitoyl Tetrapeptide-7 is a synthetic lipopeptide originally derived from immunoglobulin G (IgG) fragment research. The GQPR sequence was identified as having immunomodulatory properties, specifically the ability to suppress the production of pro-inflammatory cytokines in skin cell cultures. In the skin, chronic low-grade inflammation (sometimes termed "inflammaging") contributes to ECM degradation through persistent MMP activation and cytokine-driven collagen breakdown. Palmitoyl Tetrapeptide-7 was developed to address this inflammatory component of skin aging. It is most commonly encountered in combination with Palmitoyl Tripeptide-1 (Pal-GHK) in the commercial ingredient Matrixyl 3000, where the anti-inflammatory peptide complements the collagen-stimulatory peptide for a dual-action approach. The palmitoyl modification provides the requisite lipophilicity for topical delivery through the stratum corneum.',
                'mechanism_of_action_intro' => 'Palmitoyl Tetrapeptide-7 acts primarily as an anti-inflammatory peptide, modulating cytokine signaling and complement activation in skin cells.',
                'mechanism_subsections' => json_encode([
                    [
                        'intro' => 'The peptide targets inflammatory cascades that contribute to ECM degradation in aging and photodamaged skin.',
                        'points' => [
                            'Suppresses IL-6 secretion by keratinocytes and fibroblasts, reducing inflammation-driven MMP activation and collagen degradation',
                            'Inhibits complement cascade activation, which contributes to inflammatory tissue damage in UV-exposed skin',
                            'Reduces IL-1 and TNF-α-induced inflammatory gene expression in cultured skin cells',
                            'Palmitoyl chain enables stratum corneum penetration for topical delivery of the active tetrapeptide',
                            'Synergizes with collagen-stimulatory peptides by reducing the catabolic inflammatory environment while promoting anabolic ECM synthesis',
                        ],
                    ],
                ]),
                'preclinical_intro' => 'Palmitoyl Tetrapeptide-7 has been studied in keratinocyte and fibroblast cultures, UV-irradiation models, and skin inflammation assays.',
                'preclinical_subsections' => json_encode([
                    [
                        'title' => 'Anti-Inflammatory Studies',
                        'findings' => [
                            ['title' => 'IL-6 Suppression', 'description' => 'In cultured human keratinocytes stimulated with UV radiation or IL-1α, Palmitoyl Tetrapeptide-7 treatment reduced IL-6 secretion by 20-40% compared to stimulated untreated controls in ELISA-based assays.'],
                            ['title' => 'Complement Inhibition', 'description' => 'In complement activation assays, the peptide demonstrated inhibition of the classical complement pathway, reducing C3a and C5a generation that normally contributes to inflammatory cell recruitment and tissue damage.'],
                        ],
                    ],
                    [
                        'title' => 'Combination Studies (Matrixyl 3000)',
                        'findings' => [
                            ['title' => 'Synergistic ECM Effects', 'description' => 'The combination of Palmitoyl Tetrapeptide-7 with Palmitoyl Tripeptide-1 (Pal-GHK) showed greater net collagen accumulation than either peptide alone, attributed to simultaneous reduction in inflammatory collagen degradation and stimulation of new collagen synthesis.'],
                            ['title' => 'Photoprotection Models', 'description' => 'In UV-irradiated fibroblast cultures, the combination reduced net MMP activity more effectively than the collagen-stimulatory peptide alone, consistent with the anti-inflammatory contribution of Palmitoyl Tetrapeptide-7.'],
                        ],
                    ],
                ]),
                'preclinical_disclaimer' => 'All findings are from in-vitro cell culture experiments. Translational relevance to intact human skin in vivo requires further investigation.',
                'human_use_intro' => 'No standalone clinical trials for Palmitoyl Tetrapeptide-7 have been published. Cosmetic studies of Matrixyl 3000 (the combination product) provide indirect evidence.',
                'human_use_subsections' => json_encode([['title' => 'Clinical Evidence', 'entries' => [['type' => 'content', 'value' => 'Palmitoyl Tetrapeptide-7 has not been evaluated as a standalone compound in human clinical trials. Cosmetic efficacy data exists only for the Matrixyl 3000 combination, making it difficult to attribute observed effects specifically to the tetrapeptide component.']]]]),
                'regulatory_subsections' => json_encode([['title' => 'Regulatory Status', 'entries' => [['type' => 'content', 'value' => 'Palmitoyl Tetrapeptide-7 is a registered cosmetic ingredient (INCI). It is not approved as a drug or therapeutic agent. Research-grade material is sold for laboratory research purposes only (RUO).']]]]),
                'regulatory_important_note' => 'Research-grade Palmitoyl Tetrapeptide-7 is sold for in-vitro research purposes only. It is not approved for therapeutic use.',
                'potential_applications_intro' => 'In-vitro evidence supports research applications in skin inflammation biology and cosmetic peptide science.',
                'potential_applications' => json_encode([
                    ['title' => 'Inflammaging Research', 'description' => 'Studying the role of chronic low-grade inflammation in ECM degradation and skin aging.'],
                    ['title' => 'Cytokine Modulation Studies', 'description' => 'Investigating IL-6 and complement pathway regulation in skin cell models.'],
                    ['title' => 'Combination Peptide Research', 'description' => 'Evaluating synergistic effects of anti-inflammatory and pro-collagen peptides in skin biology.'],
                ]),
                'potential_applications_important_context' => 'All applications are based on in-vitro research. No therapeutic claims are made.',
                'conclusion' => 'Palmitoyl Tetrapeptide-7 addresses the inflammatory component of skin aging — a mechanism distinct from the collagen-stimulatory approach of most cosmetic peptides. Its ability to suppress IL-6 secretion and complement activation in skin cell models provides a rationale for its use in research investigating inflammaging and cytokine-mediated ECM degradation. The synergistic combination with Palmitoyl Tripeptide-1 in Matrixyl 3000 demonstrates the concept of multi-target cosmetic peptide strategies. However, the absence of standalone clinical data and reliance on supplier-sponsored combination studies limits definitive conclusions about its individual contribution to observed effects.',
                'references' => json_encode([
                    ['title' => 'International Journal of Cosmetic Science (2005)', 'authors' => 'Robinson LR et al.', 'links' => []],
                    ['title' => 'Journal of Cosmetic Dermatology (2012)', 'authors' => 'Schagen SK.', 'links' => []],
                ]),
                'key_points' => json_encode(['Palmitoyl Tetrapeptide-7 is an anti-inflammatory cosmetic peptide (Pal-GQPR)', 'Suppresses IL-6 secretion and complement activation in skin cell models', 'Most commonly used in combination with Pal-GHK (Matrixyl 3000)', 'Not approved for therapeutic use — research use only (RUO)']),
                'overview' => 'Palmitoyl Tetrapeptide-7 is an anti-inflammatory lipopeptide that suppresses IL-6 and complement activation in skin cell research models.',
                'areas_of_research_intro' => 'Research focuses on skin inflammation, cytokine biology, and combination peptide strategies.',
                'areas_of_research' => json_encode([
                    ['name' => 'Skin Inflammation', 'description' => 'IL-6 modulation and inflammaging research'],
                    ['name' => 'Complement Biology', 'description' => 'Classical pathway inhibition in skin models'],
                    ['name' => 'Cosmetic Peptide Science', 'description' => 'Multi-peptide combination strategies'],
                ]),
                'key_effects' => json_encode(['IL-6 secretion suppression', 'Complement cascade inhibition', 'Anti-inflammatory skin protection', 'Synergy with collagen-stimulatory peptides']),
                'common_use_cases' => json_encode(['Inflammaging research', 'Cytokine modulation studies', 'Combination peptide formulation research']),
                'how_it_works' => 'Palmitoyl Tetrapeptide-7 penetrates the stratum corneum via its lipid tail and suppresses IL-6 production in keratinocytes and fibroblasts. It also inhibits classical complement pathway activation, reducing inflammatory mediators (C3a, C5a) that drive MMP expression and collagen degradation. This anti-inflammatory activity complements collagen-stimulatory peptides by protecting existing ECM from inflammatory catabolism.',
                'rating' => '0.00',
                'rating_count' => 0,
            ],

            // ──────────────────────────────────────────────
            // 8. Nonapeptide-1
            // ──────────────────────────────────────────────
            'nonapeptide-1' => [
                'title' => 'Nonapeptide-1',
                'peptide_full_name' => 'Nonapeptide-1 (Melanostatine-5 / α-MSH Antagonist)',
                'research_title' => 'Nonapeptide-1: A Comprehensive Research Overview of the Melanogenesis Inhibitor',
                'research_outline' => 'An analysis of Nonapeptide-1, a synthetic peptide that antagonizes α-MSH signaling to modulate melanogenesis, examining its mechanism of action in melanocyte biology and skin pigmentation research.',
                'education_tag' => 'Cosmetic Peptides',
                'description' => 'Nonapeptide-1 is a synthetic nine-amino acid peptide that functions as a competitive antagonist of the melanocortin 1 receptor (MC1R). By blocking α-melanocyte-stimulating hormone (α-MSH) binding, it inhibits the melanogenesis signaling cascade, reducing melanin production in cultured melanocytes. It is studied in the context of skin pigmentation research.',
                'molecular_formula' => 'C₅₃H₈₁N₁₇O₁₂',
                'molecular_weight' => '~1,148 g/mol',
                'half_life' => 'Limited published pharmacokinetic data',
                'bioavailability' => 'Topical delivery in cosmetic research formulations',
                'background' => 'Nonapeptide-1 was developed as a targeted approach to modulating skin pigmentation by intervening at the receptor level of the melanogenesis cascade. Melanin production in melanocytes is primarily regulated by α-melanocyte-stimulating hormone (α-MSH), which binds the melanocortin 1 receptor (MC1R) on melanocyte surfaces. This activates cAMP/PKA signaling, upregulates the MITF transcription factor, and ultimately increases expression of melanogenic enzymes including tyrosinase, TRP-1, and TRP-2. Nonapeptide-1 was designed as a competitive antagonist of MC1R, blocking α-MSH binding and thereby attenuating the entire downstream melanogenesis signaling cascade. This receptor-level approach distinguishes it from direct tyrosinase inhibitors (like kojic acid or arbutin) that act further downstream in the pathway. The peptide has been incorporated into cosmetic research aimed at addressing hyperpigmentation and uneven skin tone.',
                'mechanism_of_action_intro' => 'Nonapeptide-1 inhibits melanogenesis by competing with α-MSH for binding at the MC1R receptor, blocking the upstream signal that drives melanin production.',
                'mechanism_subsections' => json_encode([
                    [
                        'intro' => 'The peptide acts at the apex of the melanogenesis signaling cascade, providing upstream modulation of melanin production.',
                        'points' => [
                            'Competitively antagonizes α-MSH binding at the melanocortin 1 receptor (MC1R) on melanocytes',
                            'Suppresses cAMP/PKA signaling downstream of MC1R, reducing MITF transcription factor activation',
                            'Decreases transcription and activity of tyrosinase, TRP-1, and TRP-2 melanogenic enzymes',
                            'Reduces melanosome maturation and melanin transfer to surrounding keratinocytes in co-culture models',
                            'Acts upstream of direct enzyme inhibitors, providing a mechanistically distinct approach to melanogenesis modulation',
                        ],
                    ],
                ]),
                'preclinical_intro' => 'Nonapeptide-1 has been evaluated in melanocyte cultures, melanocyte-keratinocyte co-culture systems, and reconstructed pigmented skin models.',
                'preclinical_subsections' => json_encode([
                    [
                        'title' => 'Melanogenesis Studies',
                        'findings' => [
                            ['title' => 'Melanin Reduction', 'description' => 'In B16 murine melanoma cells and primary human melanocytes stimulated with α-MSH, Nonapeptide-1 treatment reduced melanin content in a dose-dependent manner as measured by spectrophotometric melanin quantification.'],
                            ['title' => 'Tyrosinase Activity', 'description' => 'L-DOPA oxidation assays in Nonapeptide-1-treated melanocytes showed reduced tyrosinase enzymatic activity, consistent with upstream suppression of enzyme expression through MC1R antagonism.'],
                        ],
                    ],
                    [
                        'title' => 'Pigmented Skin Models',
                        'findings' => [
                            ['title' => 'Reconstructed Epidermis', 'description' => 'In pigmented reconstructed human epidermis models (MelanoDerm), topical Nonapeptide-1 application reduced visible pigmentation and Fontana-Masson staining intensity relative to untreated controls.'],
                            ['title' => 'Melanocyte-Keratinocyte Transfer', 'description' => 'Co-culture studies showed reduced melanosome transfer from melanocytes to keratinocytes in Nonapeptide-1-treated cultures, suggesting effects on both melanin production and distribution.'],
                        ],
                    ],
                ]),
                'preclinical_disclaimer' => 'All findings are from in-vitro melanocyte cultures and reconstructed skin models. Results may not directly predict outcomes in human skin in vivo.',
                'human_use_intro' => 'No controlled clinical trials evaluating Nonapeptide-1 as a standalone compound have been published.',
                'human_use_subsections' => json_encode([['title' => 'Clinical Evidence', 'entries' => [['type' => 'content', 'value' => 'Nonapeptide-1 has not undergone rigorous clinical evaluation. Supplier-sponsored cosmetic assessments have reported improvements in skin tone evenness, but these lack the methodological standards of pharmaceutical clinical trials.']]]]),
                'regulatory_subsections' => json_encode([['title' => 'Regulatory Status', 'entries' => [['type' => 'content', 'value' => 'Nonapeptide-1 is classified as a cosmetic ingredient. It is not approved by the FDA or EMA as a drug for treating pigmentary disorders. Research-grade Nonapeptide-1 is sold for laboratory research purposes only (RUO).']]]]),
                'regulatory_important_note' => 'Research-grade Nonapeptide-1 is sold for in-vitro research purposes only. It is not approved for therapeutic treatment of pigmentary conditions.',
                'potential_applications_intro' => 'In-vitro data supports research applications in melanocyte biology and pigmentation science.',
                'potential_applications' => json_encode([
                    ['title' => 'Melanogenesis Pathway Research', 'description' => 'Studying MC1R antagonism and its downstream effects on MITF, tyrosinase, and melanin production.'],
                    ['title' => 'Pigmentation Biology', 'description' => 'Investigating melanocyte-keratinocyte interactions and melanosome transfer mechanisms.'],
                ]),
                'potential_applications_important_context' => 'All applications are based on in-vitro research. No therapeutic claims are made for pigmentary conditions.',
                'conclusion' => 'Nonapeptide-1 provides a receptor-level approach to melanogenesis modulation that is mechanistically distinct from direct tyrosinase inhibitors. By antagonizing α-MSH at MC1R, it attenuates the entire downstream melanin production cascade, including enzyme expression, melanosome maturation, and melanin transfer. In-vitro evidence supports its efficacy in reducing melanin production in cell culture and pigmented skin models. However, the translation from in-vitro melanocyte assays to clinically meaningful skin lightening effects in vivo remains unestablished through rigorous clinical trials. Nonapeptide-1 is a research tool for investigating melanocortin signaling and pigmentation biology.',
                'references' => json_encode([
                    ['title' => 'Pigment Cell Research (2003)', 'authors' => 'Brenner M, Hearing VJ.', 'links' => []],
                    ['title' => 'Journal of Cosmetic Dermatology (2007)', 'authors' => 'Gorouhi F, Maibach HI.', 'links' => []],
                ]),
                'key_points' => json_encode(['Nonapeptide-1 is a competitive antagonist of α-MSH at the MC1R receptor', 'Suppresses cAMP/MITF/tyrosinase melanogenesis cascade upstream', 'Reduces melanin production and melanosome transfer in vitro', 'Not approved for therapeutic use — research use only (RUO)']),
                'overview' => 'Nonapeptide-1 is a melanogenesis inhibitor that antagonizes α-MSH at MC1R to reduce melanin production in skin cell research models.',
                'areas_of_research_intro' => 'Research focuses on melanocyte biology, MC1R signaling, and pigmentation science.',
                'areas_of_research' => json_encode([
                    ['name' => 'Melanocyte Biology', 'description' => 'MC1R antagonism and melanogenesis pathway modulation'],
                    ['name' => 'Pigmentation Science', 'description' => 'Melanin production and melanosome transfer research'],
                ]),
                'key_effects' => json_encode(['MC1R competitive antagonism', 'Melanin synthesis reduction', 'Tyrosinase expression suppression', 'Melanosome transfer modulation']),
                'common_use_cases' => json_encode(['Melanogenesis pathway research', 'MC1R signaling studies', 'Pigmentation biology experiments']),
                'how_it_works' => 'Nonapeptide-1 competitively blocks α-MSH binding at MC1R on melanocytes, preventing activation of the cAMP/PKA/MITF signaling cascade. This reduces transcription of melanogenic enzymes (tyrosinase, TRP-1, TRP-2), decreasing melanin synthesis and melanosome maturation. The upstream mechanism distinguishes it from direct enzyme inhibitors.',
                'rating' => '0.00',
                'rating_count' => 0,
            ],

            // ──────────────────────────────────────────────
            // 9. Acetyl Hexapeptide-3 (Argireline)
            // ──────────────────────────────────────────────
            'acetyl-hexapeptide-3-argireline' => [
                'title' => 'Acetyl Hexapeptide-3 (Argireline)',
                'peptide_full_name' => 'Acetyl-Glu-Glu-Met-Gln-Arg-Arg-NH₂',
                'research_title' => 'Argireline (Acetyl Hexapeptide-3): A Comprehensive Research Overview',
                'research_outline' => 'An analysis of Argireline, a synthetic hexapeptide studied for its effects on SNARE complex assembly and neurotransmitter release modulation in the context of expression line research.',
                'education_tag' => 'Cosmetic Peptides',
                'description' => 'Argireline (Acetyl Hexapeptide-3) is a synthetic hexapeptide derived from the N-terminal sequence of SNAP-25 (Synaptosome-Associated Protein of 25 kDa). It competes with native SNAP-25 for incorporation into the SNARE complex, modulating vesicular neurotransmitter release at the neuromuscular junction in cell culture models. It is studied in cosmetic research targeting expression lines.',
                'molecular_formula' => 'C₃₄H₆₀N₁₄O₁₂S',
                'molecular_weight' => '888.97 g/mol',
                'half_life' => 'Limited published pharmacokinetic data',
                'bioavailability' => 'Topical delivery in cosmetic research formulations',
                'background' => 'Argireline (Acetyl Hexapeptide-3, also known as Acetyl Hexapeptide-8 under updated INCI nomenclature) was developed by Lipotec (now part of Lubrizol) as a topical peptide targeting the mechanism underlying expression-related skin creasing. The concept was inspired by the mechanism of botulinum neurotoxin, which cleaves SNARE complex proteins to prevent vesicular neurotransmitter release. Rather than cleaving SNARE proteins, Argireline was designed as a competitive inhibitor — its sequence mimics the N-terminal domain of SNAP-25, competing with native SNAP-25 for assembly into the SNARE complex (comprising SNAP-25, syntaxin, and VAMP/synaptobrevin). By reducing SNARE complex formation, the peptide attenuates acetylcholine release at the neuromuscular junction, theoretically reducing the muscular contractions that contribute to expression lines. Argireline became one of the most commercially successful cosmetic peptides, marketed as a topical alternative to neurotoxin injections.',
                'mechanism_of_action_intro' => 'Argireline modulates neuromuscular junction signaling by interfering with SNARE complex assembly, which is required for synaptic vesicle fusion and neurotransmitter release.',
                'mechanism_subsections' => json_encode([
                    [
                        'intro' => 'The peptide acts on the presynaptic side of the neuromuscular junction by competing with native SNAP-25 in SNARE complex formation.',
                        'points' => [
                            'Mimics the N-terminal domain of SNAP-25, competing for incorporation into the SNARE complex',
                            'Reduces functional SNARE complex assembly (SNAP-25 + syntaxin + VAMP), which is required for synaptic vesicle exocytosis',
                            'Attenuates catecholamine and neurotransmitter release in chromaffin cell and neuronal culture models',
                            'Does not cleave SNARE proteins (unlike botulinum toxin) — acts as a competitive modulator rather than an enzymatic inhibitor',
                            'Effects are concentration-dependent and reversible upon peptide removal in cell culture',
                        ],
                    ],
                ]),
                'preclinical_intro' => 'Argireline has been evaluated in chromaffin cell models, neuronal cultures, and cosmetic skin studies.',
                'preclinical_subsections' => json_encode([
                    [
                        'title' => 'SNARE Complex and Neurotransmission Studies',
                        'findings' => [
                            ['title' => 'Catecholamine Release', 'description' => 'In bovine adrenal chromaffin cells, Argireline treatment reduced nicotine-stimulated catecholamine release in a dose-dependent manner, confirming interference with SNARE-mediated vesicle exocytosis. Maximum inhibition of approximately 40% was observed at high concentrations.'],
                            ['title' => 'SNARE Complex Formation', 'description' => 'Immunoprecipitation studies demonstrated that Argireline reduces the amount of functional SNARE complexes formed in treated cells, consistent with competitive displacement of native SNAP-25.'],
                        ],
                    ],
                    [
                        'title' => 'Skin Model Studies',
                        'findings' => [
                            ['title' => 'Expression Line Models', 'description' => 'Supplier-sponsored studies using skin surface profilometry reported reductions in wrinkle depth around the periorbital region following 4 weeks of topical Argireline application at 10% concentration.'],
                            ['title' => 'Penetration Considerations', 'description' => 'A key debate in the literature concerns whether sufficient concentrations of Argireline can penetrate through the stratum corneum, epidermis, and dermis to reach the neuromuscular junction underlying facial skin in vivo.'],
                        ],
                    ],
                ]),
                'preclinical_disclaimer' => 'In-vitro neurotransmission effects were demonstrated in cell culture models. Whether topically applied Argireline reaches the neuromuscular junction in sufficient concentrations in vivo remains a subject of ongoing research debate.',
                'human_use_intro' => 'Limited cosmetic efficacy studies have been published, primarily by the ingredient supplier. No pharmaceutical-grade clinical trials exist.',
                'human_use_subsections' => json_encode([['title' => 'Cosmetic Studies', 'entries' => [['type' => 'content', 'value' => 'Supplier studies reported reductions in periorbital wrinkle depth following topical Argireline application. Independent academic evaluation of these claims is limited, and the fundamental question of whether topical application achieves biologically relevant concentrations at the neuromuscular junction level remains open.']]]]),
                'regulatory_subsections' => json_encode([['title' => 'Regulatory Status', 'entries' => [['type' => 'content', 'value' => 'Acetyl Hexapeptide-3/8 is a registered cosmetic ingredient (INCI). It is not approved as a drug or therapeutic alternative to botulinum neurotoxin. Research-grade Argireline is sold for laboratory research purposes only (RUO).']]]]),
                'regulatory_important_note' => 'Research-grade Argireline is sold for in-vitro research purposes only. It is not a therapeutic agent or substitute for any approved medical treatment.',
                'potential_applications_intro' => 'In-vitro evidence supports research applications in synaptic biology and neuromuscular signaling.',
                'potential_applications' => json_encode([
                    ['title' => 'SNARE Complex Biology', 'description' => 'Studying SNARE assembly dynamics and vesicle exocytosis mechanisms in cell culture models.'],
                    ['title' => 'Neuromuscular Junction Research', 'description' => 'Investigating non-enzymatic modulation of neurotransmitter release at synaptic junctions.'],
                    ['title' => 'Cosmetic Peptide Science', 'description' => 'Evaluating neuromuscular-targeting peptide delivery and efficacy in skin models.'],
                ]),
                'potential_applications_important_context' => 'All applications are based on in-vitro research. No therapeutic claims are made.',
                'conclusion' => 'Argireline represents an innovative approach to cosmetic peptide design, translating the molecular mechanism of botulinum neurotoxin into a competitive peptide inhibitor of SNARE complex assembly. Its in-vitro efficacy in reducing catecholamine release from chromaffin cells is well-documented. However, the critical translational question — whether topical application delivers sufficient peptide to the neuromuscular junction through multiple tissue layers — remains incompletely resolved. This fundamental delivery challenge distinguishes Argireline from injectable neurotoxins and underscores the importance of distinguishing between in-vitro mechanism demonstration and in-vivo clinical efficacy. Argireline continues to serve as a valuable research tool for studying SNARE biology and as a reference compound in cosmetic peptide science.',
                'references' => json_encode([
                    ['title' => 'International Journal of Cosmetic Science (2002)', 'authors' => 'Blanes-Mira C et al.', 'links' => []],
                    ['title' => 'Biochemical Society Transactions (2003)', 'authors' => 'Blanes-Mira C et al.', 'links' => []],
                ]),
                'key_points' => json_encode(['Argireline mimics SNAP-25 to competitively inhibit SNARE complex assembly', 'Reduces catecholamine release in chromaffin cell models by up to 40%', 'Topical penetration to the neuromuscular junction remains debated', 'Not approved as a therapeutic agent — research use only (RUO)']),
                'overview' => 'Argireline is a hexapeptide that modulates SNARE complex assembly to attenuate neurotransmitter release in cosmetic neuromuscular research.',
                'areas_of_research_intro' => 'Research spans SNARE biology, synaptic vesicle exocytosis, and cosmetic peptide science.',
                'areas_of_research' => json_encode([
                    ['name' => 'SNARE Biology', 'description' => 'SNARE complex assembly and vesicle fusion mechanisms'],
                    ['name' => 'Neuromuscular Research', 'description' => 'Neurotransmitter release modulation at synaptic junctions'],
                    ['name' => 'Cosmetic Science', 'description' => 'Expression line targeting and topical peptide delivery'],
                ]),
                'key_effects' => json_encode(['SNARE complex assembly inhibition', 'Catecholamine release reduction', 'SNAP-25 competitive modulation', 'Reversible and concentration-dependent']),
                'common_use_cases' => json_encode(['SNARE complex research', 'Vesicle exocytosis studies', 'Cosmetic neuromuscular peptide research']),
                'how_it_works' => 'Argireline mimics the N-terminal domain of SNAP-25 and competes for its position in the SNARE complex (SNAP-25 + syntaxin + VAMP). Reduced functional SNARE assembly decreases synaptic vesicle fusion and neurotransmitter release. Unlike botulinum toxin, it does not cleave proteins — its effects are competitive and reversible.',
                'rating' => '0.00',
                'rating_count' => 0,
            ],

            // ──────────────────────────────────────────────
            // 10. Tripeptide-29
            // ──────────────────────────────────────────────
            'tripeptide-29' => [
                'title' => 'Tripeptide-29',
                'peptide_full_name' => 'Glycyl-Prolyl-Hydroxyproline (Gly-Pro-Hyp)',
                'research_title' => 'Tripeptide-29 (Gly-Pro-Hyp): A Comprehensive Research Overview',
                'research_outline' => 'An analysis of Tripeptide-29, a collagen-derived tripeptide fragment with collagen synthesis-stimulatory properties in dermal fibroblast research.',
                'education_tag' => 'Cosmetic Peptides',
                'description' => 'Tripeptide-29 (Gly-Pro-Hyp) is the most abundant tripeptide repeat unit of collagen, derived from the characteristic Gly-X-Y repeat structure where X is frequently proline and Y is frequently hydroxyproline. As a collagen fragment, it functions as a matrikine that signals fibroblasts to produce new collagen, effectively serving as a biological indicator of collagen turnover.',
                'molecular_formula' => 'C₁₂H₁₉N₃O₅',
                'molecular_weight' => '285.30 g/mol',
                'half_life' => 'Short (small peptide subject to rapid enzymatic degradation)',
                'bioavailability' => 'Dependent on formulation and delivery system',
                'background' => 'Tripeptide-29 is the fundamental repetitive unit of fibrillar collagen — the Gly-Pro-Hyp sequence that characterizes the collagen triple helix. Approximately 10% of collagen consists of this exact tripeptide repeat, making it the most abundant fragment released during collagen degradation by matrix metalloproteinases. As a collagen-derived matrikine, Tripeptide-29 signals to fibroblasts that collagen turnover is occurring, stimulating compensatory new collagen biosynthesis. This feedback mechanism is central to collagen homeostasis in connective tissues. In cosmetic research, Tripeptide-29 has been investigated for its ability to promote collagen production in dermal fibroblast cultures. Its small size facilitates cellular uptake, though it also makes it susceptible to rapid enzymatic degradation. Collagen-derived peptides including Gly-Pro-Hyp have been studied in the broader context of collagen hydrolysate bioactivity, where oral ingestion of collagen fragments has been investigated for effects on skin and joint parameters.',
                'mechanism_of_action_intro' => 'Tripeptide-29 functions as a matrikine — a collagen degradation fragment that activates fibroblast collagen biosynthesis through receptor-mediated signaling.',
                'mechanism_subsections' => json_encode([
                    [
                        'intro' => 'The peptide triggers collagen synthesis feedback through its recognition as a collagen turnover signal by dermal fibroblasts.',
                        'points' => [
                            'Recognized by fibroblasts as a collagen degradation product, triggering compensatory collagen biosynthesis',
                            'Stimulates procollagen I and procollagen III gene transcription through TGF-β-related signaling pathways',
                            'Activates integrin receptors on fibroblasts, initiating focal adhesion kinase (FAK) signaling',
                            'Promotes prolyl hydroxylase and lysyl hydroxylase expression required for collagen post-translational modification',
                            'Small molecular size facilitates cellular uptake and intracellular signaling engagement',
                        ],
                    ],
                ]),
                'preclinical_intro' => 'Tripeptide-29 has been studied in fibroblast cultures, collagen hydrolysate bioactivity studies, and skin cell models.',
                'preclinical_subsections' => json_encode([
                    [
                        'title' => 'Collagen Synthesis Studies',
                        'findings' => [
                            ['title' => 'Fibroblast Stimulation', 'description' => 'In cultured human dermal fibroblasts, Gly-Pro-Hyp treatment increased procollagen I C-terminal peptide (PICP) secretion in a dose-dependent manner, confirming its collagen synthesis-stimulatory activity as a matrikine.'],
                            ['title' => 'Collagen Hydrolysate Research', 'description' => 'Gly-Pro-Hyp has been identified as a bioactive component in collagen hydrolysate preparations, contributing to the observed effects of collagen peptide supplements on fibroblast activity in vitro.'],
                        ],
                    ],
                    [
                        'title' => 'Mechanistic Studies',
                        'findings' => [
                            ['title' => 'Chemotactic Activity', 'description' => 'Gly-Pro-Hyp demonstrates chemotactic activity for fibroblasts, promoting cell migration toward sites of collagen degradation — a mechanism relevant to wound healing and tissue remodeling.'],
                            ['title' => 'Prolyl Hydroxylase Induction', 'description' => 'Treatment with Gly-Pro-Hyp upregulates prolyl-4-hydroxylase expression in fibroblasts, supporting the post-translational hydroxylation essential for stable triple helix formation in newly synthesized collagen.'],
                        ],
                    ],
                ]),
                'preclinical_disclaimer' => 'All findings are from in-vitro cell culture experiments. Results may not directly predict in-vivo outcomes.',
                'human_use_intro' => 'No controlled clinical trials for Tripeptide-29 as a standalone topical ingredient have been published.',
                'human_use_subsections' => json_encode([['title' => 'Clinical Evidence', 'entries' => [['type' => 'content', 'value' => 'Tripeptide-29 has not been evaluated in standalone clinical trials. Related research on oral collagen hydrolysates (which contain Gly-Pro-Hyp among many other fragments) has shown effects on skin hydration and elasticity parameters, but these cannot be attributed to Tripeptide-29 alone.']]]]),
                'regulatory_subsections' => json_encode([['title' => 'Regulatory Status', 'entries' => [['type' => 'content', 'value' => 'Tripeptide-29 is classified as a cosmetic ingredient. It is not approved as a drug or therapeutic agent. Research-grade material is sold for laboratory research purposes only (RUO).']]]]),
                'regulatory_important_note' => 'Research-grade Tripeptide-29 is sold for in-vitro research purposes only. It is not approved for therapeutic use.',
                'potential_applications_intro' => 'In-vitro data supports research applications in collagen biology and ECM homeostasis.',
                'potential_applications' => json_encode([
                    ['title' => 'Collagen Homeostasis Research', 'description' => 'Studying the matrikine feedback loop in collagen turnover and fibroblast activation.'],
                    ['title' => 'Wound Healing Biology', 'description' => 'Investigating fibroblast chemotaxis and ECM repair signaling mechanisms.'],
                ]),
                'potential_applications_important_context' => 'All applications are based on in-vitro research. No therapeutic claims are made.',
                'conclusion' => 'Tripeptide-29 (Gly-Pro-Hyp) represents the fundamental collagen building block repurposed as a signaling molecule. Its matrikine activity — signaling fibroblasts to produce new collagen in response to detected collagen degradation — illustrates the elegant feedback mechanisms that maintain ECM homeostasis. While conceptually straightforward, the translational challenges of delivering a small, rapidly degradable tripeptide to dermal fibroblasts in sufficient concentrations remain. Tripeptide-29 serves as a valuable research tool for understanding collagen biology and matrikine signaling.',
                'references' => json_encode([
                    ['title' => 'Journal of Biological Chemistry (2005)', 'authors' => 'Ohara H et al.', 'links' => []],
                    ['title' => 'Food and Function (2014)', 'authors' => 'Iwai K et al.', 'links' => []],
                ]),
                'key_points' => json_encode(['Tripeptide-29 (Gly-Pro-Hyp) is the most abundant collagen repeat unit', 'Acts as a matrikine signaling collagen turnover to stimulate fibroblast biosynthesis', 'Demonstrates chemotactic activity for fibroblasts in vitro', 'Not approved for therapeutic use — research use only (RUO)']),
                'overview' => 'Tripeptide-29 is a collagen-derived matrikine that signals fibroblasts to produce new collagen in response to ECM turnover.',
                'areas_of_research_intro' => 'Research spans collagen biology, matrikine signaling, and ECM homeostasis.',
                'areas_of_research' => json_encode([
                    ['name' => 'Collagen Biology', 'description' => 'Collagen fragment signaling and synthesis feedback'],
                    ['name' => 'ECM Homeostasis', 'description' => 'Matrikine-driven tissue remodeling mechanisms'],
                ]),
                'key_effects' => json_encode(['Collagen synthesis stimulation', 'Fibroblast chemotactic activity', 'Matrikine signaling activation', 'Prolyl hydroxylase induction']),
                'common_use_cases' => json_encode(['Collagen biology research', 'Matrikine signaling studies', 'Fibroblast activation experiments']),
                'how_it_works' => 'Tripeptide-29 is recognized by fibroblasts as a collagen degradation fragment, triggering compensatory collagen biosynthesis through integrin-mediated FAK signaling and TGF-β pathway activation. It promotes procollagen I/III transcription, prolyl hydroxylase expression for collagen hydroxylation, and fibroblast chemotaxis toward sites of collagen turnover.',
                'rating' => '0.00',
                'rating_count' => 0,
            ],

            // ──────────────────────────────────────────────
            // 11. Syn-Coll (Palmitoyl Tripeptide-5)
            // ──────────────────────────────────────────────
            'syn-coll-palmitoyl-tripeptide-5' => [
                'title' => 'Syn-Coll (Palmitoyl Tripeptide-5)',
                'peptide_full_name' => 'Palmitoyl-Lys-Val-Lys (TGF-β Mimetic Peptide)',
                'research_title' => 'Syn-Coll (Palmitoyl Tripeptide-5): A Comprehensive Research Overview',
                'research_outline' => 'An analysis of Syn-Coll, a TGF-β mimetic peptide designed to stimulate collagen production by activating growth factor signaling pathways in dermal fibroblast research.',
                'education_tag' => 'Cosmetic Peptides',
                'description' => 'Syn-Coll (Palmitoyl Tripeptide-5) is a synthetic lipopeptide designed to mimic the collagen-stimulatory activity of transforming growth factor beta (TGF-β). It activates TGF-β receptor signaling in dermal fibroblasts, promoting procollagen synthesis through Smad-dependent transcriptional pathways.',
                'molecular_formula' => 'C₃₂H₆₂N₄O₅',
                'molecular_weight' => '582.87 g/mol',
                'half_life' => 'Extended relative to unmodified tripeptide (specific data limited)',
                'bioavailability' => 'Enhanced topical penetration via palmitoyl modification',
                'background' => 'Syn-Coll (Palmitoyl Tripeptide-5) was developed by DSM as a biomimetic peptide designed to replicate the collagen-stimulatory effects of TGF-β without the complexity and instability of the full growth factor protein. TGF-β is the primary physiological driver of collagen gene transcription in fibroblasts, acting through TGF-β type I and type II receptor-mediated Smad2/3 signaling. The Lys-Val-Lys (KVK) tripeptide sequence was identified as a minimal motif capable of engaging TGF-β signaling pathways, and palmitoyl conjugation was added to enable topical delivery. By acting as a growth factor mimetic rather than a matrikine (collagen fragment), Syn-Coll represents a mechanistically distinct approach to stimulating collagen production compared to peptides like Matrixyl (KTTKS). This TGF-β-mimetic strategy directly targets the signaling cascade that controls collagen gene transcription in fibroblasts.',
                'mechanism_of_action_intro' => 'Syn-Coll activates TGF-β receptor signaling to stimulate collagen gene transcription through the canonical Smad-dependent pathway.',
                'mechanism_subsections' => json_encode([
                    [
                        'intro' => 'As a growth factor mimetic, Syn-Coll directly engages TGF-β signaling rather than relying on indirect matrikine feedback.',
                        'points' => [
                            'Activates TGF-β receptor-mediated Smad2/3 phosphorylation and nuclear translocation',
                            'Promotes Smad-dependent transcription of COL1A1 and COL1A2 collagen genes',
                            'Stimulates HSP47 (heat shock protein 47) expression, a collagen-specific molecular chaperone required for proper procollagen folding',
                            'Palmitoyl chain enables stratum corneum penetration for topical delivery',
                            'Increases tissue inhibitor of metalloproteinase (TIMP) expression, shifting the MMP/TIMP balance toward net collagen accumulation',
                        ],
                    ],
                ]),
                'preclinical_intro' => 'Syn-Coll has been evaluated in dermal fibroblast cultures and skin model systems, with particular focus on TGF-β pathway activation.',
                'preclinical_subsections' => json_encode([
                    [
                        'title' => 'TGF-β Pathway Activation',
                        'findings' => [
                            ['title' => 'Smad Signaling', 'description' => 'Western blot analysis of Palmitoyl Tripeptide-5-treated fibroblasts showed increased phospho-Smad2/3 levels, confirming engagement of the canonical TGF-β signaling pathway without exogenous TGF-β growth factor.'],
                            ['title' => 'Collagen Gene Expression', 'description' => 'qRT-PCR analysis demonstrated upregulation of COL1A1, COL1A2, and COL3A1 mRNA in fibroblasts treated with Syn-Coll, with dose-dependent responses at concentrations of 10⁻⁸ to 10⁻⁵ M.'],
                        ],
                    ],
                    [
                        'title' => 'Functional ECM Studies',
                        'findings' => [
                            ['title' => 'Procollagen Secretion', 'description' => 'PICP ELISA quantification showed increased procollagen I secretion from Syn-Coll-treated fibroblasts, with comparable efficacy to low concentrations of recombinant TGF-β1 in the same assay system.'],
                            ['title' => 'HSP47 Induction', 'description' => 'Syn-Coll treatment upregulated HSP47, the collagen-specific chaperone, indicating not only increased collagen transcription but enhanced quality control of procollagen folding and secretion.'],
                        ],
                    ],
                ]),
                'preclinical_disclaimer' => 'All findings are from in-vitro cell culture experiments. Results may not directly predict in-vivo human outcomes.',
                'human_use_intro' => 'No controlled clinical trials for Syn-Coll have been published in the peer-reviewed literature.',
                'human_use_subsections' => json_encode([['title' => 'Clinical Evidence', 'entries' => [['type' => 'content', 'value' => 'Supplier-sponsored assessments have reported improvements in wrinkle reduction and skin firmness parameters. These studies lack independent verification and pharmaceutical-grade trial design.']]]]),
                'regulatory_subsections' => json_encode([['title' => 'Regulatory Status', 'entries' => [['type' => 'content', 'value' => 'Palmitoyl Tripeptide-5 is a registered cosmetic ingredient (INCI). It is not approved as a drug or therapeutic agent. Research-grade material is sold for laboratory research purposes only (RUO).']]]]),
                'regulatory_important_note' => 'Research-grade Syn-Coll is sold for in-vitro research purposes only. It is not approved for therapeutic use.',
                'potential_applications_intro' => 'In-vitro data supports research applications in TGF-β signaling and collagen biology.',
                'potential_applications' => json_encode([
                    ['title' => 'Growth Factor Mimetic Research', 'description' => 'Studying minimal peptide sequences capable of activating TGF-β receptor signaling.'],
                    ['title' => 'Collagen Quality Control', 'description' => 'Investigating HSP47 induction and procollagen folding quality in fibroblast models.'],
                ]),
                'potential_applications_important_context' => 'All applications are based on in-vitro research. No therapeutic claims are made.',
                'conclusion' => 'Syn-Coll represents a growth factor mimetic approach to collagen stimulation that is mechanistically distinct from matrikine peptides. By directly engaging TGF-β/Smad signaling, it targets the master regulatory pathway for collagen gene transcription in fibroblasts. The additional induction of HSP47 suggests effects on collagen quality control beyond simple transcriptional upregulation. However, the translation from in-vitro TGF-β pathway activation to clinically meaningful anti-aging effects requires further validation through rigorous clinical investigation.',
                'references' => json_encode([
                    ['title' => 'Journal of Cosmetic Dermatology (2009)', 'authors' => 'Lintner K.', 'links' => []],
                    ['title' => 'International Journal of Cosmetic Science (2012)', 'authors' => 'Schagen SK.', 'links' => []],
                ]),
                'key_points' => json_encode(['Syn-Coll is a TGF-β mimetic lipopeptide (Pal-KVK) for collagen stimulation', 'Activates Smad2/3 signaling and collagen gene transcription in fibroblasts', 'Induces HSP47 collagen chaperone for quality control of procollagen folding', 'Not approved for therapeutic use — research use only (RUO)']),
                'overview' => 'Syn-Coll is a TGF-β mimetic lipopeptide that stimulates collagen gene transcription through Smad signaling in dermal fibroblast research.',
                'areas_of_research_intro' => 'Research focuses on TGF-β signaling, collagen biosynthesis, and growth factor mimicry.',
                'areas_of_research' => json_encode([
                    ['name' => 'TGF-β Signaling', 'description' => 'Smad pathway activation and collagen gene regulation'],
                    ['name' => 'Collagen Biology', 'description' => 'Procollagen synthesis and HSP47 chaperone function'],
                ]),
                'key_effects' => json_encode(['TGF-β/Smad pathway activation', 'Collagen gene transcription stimulation', 'HSP47 chaperone induction', 'TIMP upregulation']),
                'common_use_cases' => json_encode(['TGF-β signaling research', 'Growth factor mimetic studies', 'Collagen synthesis research']),
                'how_it_works' => 'Syn-Coll activates TGF-β type I and type II receptors, triggering Smad2/3 phosphorylation and nuclear translocation. This drives transcription of COL1A1/COL1A2 collagen genes and HSP47 chaperone. The palmitoyl chain enables topical delivery through the stratum corneum. Unlike matrikines, it acts as a direct growth factor mimetic rather than a collagen degradation signal.',
                'rating' => '0.00',
                'rating_count' => 0,
            ],

            // ──────────────────────────────────────────────
            // 12. Vialox (Pentapeptide-3V)
            // ──────────────────────────────────────────────
            'vialox-pentapeptide-3v' => [
                'title' => 'Vialox (Pentapeptide-3V)',
                'peptide_full_name' => 'Pentapeptide-3 (Tubocurarine-Mimetic Peptide)',
                'research_title' => 'Vialox (Pentapeptide-3V): A Comprehensive Research Overview',
                'research_outline' => 'An analysis of Vialox, a synthetic pentapeptide designed to mimic the neuromuscular blocking activity of tubocurarine at the postsynaptic nicotinic acetylcholine receptor in skin research models.',
                'education_tag' => 'Cosmetic Peptides',
                'description' => 'Vialox (Pentapeptide-3V) is a synthetic pentapeptide designed to competitively antagonize the nicotinic acetylcholine receptor (nAChR) at the postsynaptic side of the neuromuscular junction. Its mechanism is modeled after tubocurarine (curare), a classic competitive neuromuscular blocking agent, and it is studied in the context of expression line research.',
                'molecular_formula' => 'C₃₅H₆₀N₈O₉',
                'molecular_weight' => '~736.9 g/mol',
                'half_life' => 'Limited published pharmacokinetic data',
                'bioavailability' => 'Topical delivery in research formulations',
                'background' => 'Vialox (Pentapeptide-3V) was developed by DSM as a cosmetic peptide targeting the postsynaptic side of the neuromuscular junction — a mechanistically distinct approach from Argireline, which targets the presynaptic SNARE complex. Vialox was designed to mimic the competitive antagonism of tubocurarine (curare) at the nicotinic acetylcholine receptor (nAChR). Tubocurarine is a classic pharmacological agent that blocks acetylcholine binding at the postsynaptic motor endplate, preventing muscular contraction. By designing a small peptide that competes for the acetylcholine binding site on the nAChR, researchers sought to create a topically deliverable molecule that could modulate neuromuscular transmission underlying facial expression lines. The pentapeptide sequence was optimized to interact with the alpha subunit of the nAChR at the acetylcholine binding domain.',
                'mechanism_of_action_intro' => 'Vialox acts at the postsynaptic neuromuscular junction by competing with acetylcholine for binding at the nicotinic acetylcholine receptor.',
                'mechanism_subsections' => json_encode([
                    [
                        'intro' => 'The peptide mimics the competitive antagonism of tubocurarine, blocking signal transmission at the motor endplate.',
                        'points' => [
                            'Competitively antagonizes acetylcholine at the α-subunit of the nicotinic acetylcholine receptor (nAChR)',
                            'Blocks sodium channel opening and depolarization at the postsynaptic motor endplate',
                            'Reduces muscle fiber contraction response in neuromuscular junction models',
                            'Acts on the postsynaptic side — mechanistically distinct from presynaptic SNARE inhibitors (Argireline) and botulinum toxin',
                            'Effects are competitive, concentration-dependent, and reversible',
                        ],
                    ],
                ]),
                'preclinical_intro' => 'Vialox has been evaluated in neuromuscular junction models and cosmetic research assays.',
                'preclinical_subsections' => json_encode([
                    [
                        'title' => 'Neuromuscular Junction Studies',
                        'findings' => [
                            ['title' => 'nAChR Binding', 'description' => 'In competitive binding assays, Pentapeptide-3V demonstrated affinity for the nicotinic acetylcholine receptor, competing with radiolabeled acetylcholine analogs for binding at the receptor alpha subunit.'],
                            ['title' => 'Muscle Contraction Modulation', 'description' => 'In isolated muscle preparation models, Pentapeptide-3V reduced evoked contraction amplitude in a dose-dependent manner, consistent with postsynaptic neuromuscular blockade.'],
                        ],
                    ],
                    [
                        'title' => 'Cosmetic Research',
                        'findings' => [
                            ['title' => 'Expression Line Assessment', 'description' => 'Supplier assessments reported reductions in forehead expression line measurements in volunteers using Pentapeptide-3V formulations over 28-day application periods.'],
                            ['title' => 'Penetration Considerations', 'description' => 'As with other neuromuscular-targeting cosmetic peptides, the fundamental question of whether topical application achieves sufficient concentration at the neuromuscular junction remains a subject of research.'],
                        ],
                    ],
                ]),
                'preclinical_disclaimer' => 'In-vitro and ex-vivo findings may not directly predict outcomes from topical application to human skin.',
                'human_use_intro' => 'No controlled clinical trials for Vialox have been published in peer-reviewed literature.',
                'human_use_subsections' => json_encode([['title' => 'Clinical Evidence', 'entries' => [['type' => 'content', 'value' => 'Vialox has not undergone rigorous clinical evaluation. Available data comes from supplier-sponsored cosmetic assessments with limited methodological reporting.']]]]),
                'regulatory_subsections' => json_encode([['title' => 'Regulatory Status', 'entries' => [['type' => 'content', 'value' => 'Pentapeptide-3 is a cosmetic ingredient. It is not approved as a neuromuscular blocking agent or therapeutic compound. Research-grade material is sold for laboratory research purposes only (RUO).']]]]),
                'regulatory_important_note' => 'Research-grade Vialox is sold for in-vitro research purposes only. It is not a therapeutic neuromuscular blocking agent.',
                'potential_applications_intro' => 'In-vitro data supports research applications in neuromuscular junction pharmacology.',
                'potential_applications' => json_encode([
                    ['title' => 'nAChR Pharmacology', 'description' => 'Studying peptide-based competitive antagonism at nicotinic acetylcholine receptors.'],
                    ['title' => 'Neuromuscular Junction Research', 'description' => 'Investigating postsynaptic mechanisms of neuromuscular transmission modulation.'],
                ]),
                'potential_applications_important_context' => 'All applications are based on in-vitro research. No therapeutic claims are made.',
                'conclusion' => 'Vialox represents an innovative postsynaptic approach to neuromuscular modulation in cosmetic peptide research. By targeting the nAChR rather than presynaptic SNARE proteins, it provides a mechanistically distinct tool for studying neuromuscular junction pharmacology. In-vitro evidence supports its competitive antagonism at the receptor, but the translational challenges of topical delivery to deeply situated neuromuscular junctions remain significant. Vialox serves as a research tool for nAChR pharmacology and cosmetic peptide mechanism studies.',
                'references' => json_encode([
                    ['title' => 'International Journal of Cosmetic Science (2005)', 'authors' => 'Lintner K.', 'links' => []],
                    ['title' => 'Pharmacological Reviews (1978)', 'authors' => 'Bowman WC.', 'links' => []],
                ]),
                'key_points' => json_encode(['Vialox mimics tubocurarine as a competitive nAChR antagonist at the postsynaptic motor endplate', 'Blocks acetylcholine binding and motor endplate depolarization', 'Mechanistically distinct from presynaptic SNARE inhibitors (Argireline)', 'Not approved for therapeutic use — research use only (RUO)']),
                'overview' => 'Vialox is a tubocurarine-mimetic pentapeptide that competitively antagonizes the nicotinic acetylcholine receptor in neuromuscular research.',
                'areas_of_research_intro' => 'Research spans nAChR pharmacology, neuromuscular biology, and cosmetic peptide science.',
                'areas_of_research' => json_encode([
                    ['name' => 'nAChR Pharmacology', 'description' => 'Competitive antagonism at nicotinic receptors'],
                    ['name' => 'Neuromuscular Biology', 'description' => 'Postsynaptic transmission modulation'],
                ]),
                'key_effects' => json_encode(['nAChR competitive antagonism', 'Motor endplate depolarization blockade', 'Muscle contraction modulation', 'Reversible postsynaptic effects']),
                'common_use_cases' => json_encode(['nAChR receptor binding research', 'Neuromuscular junction studies', 'Cosmetic peptide mechanism research']),
                'how_it_works' => 'Vialox competes with acetylcholine for binding at the α-subunit of the nicotinic acetylcholine receptor on the postsynaptic motor endplate. This blocks sodium channel opening and prevents depolarization, reducing muscle contraction. Unlike Argireline (presynaptic) or botulinum toxin (enzymatic), Vialox acts through reversible competitive antagonism at the postsynaptic receptor.',
                'rating' => '0.00',
                'rating_count' => 0,
            ],

            // ──────────────────────────────────────────────
            // 13. Decapeptide-12
            // ──────────────────────────────────────────────
            'decapeptide-12' => [
                'title' => 'Decapeptide-12',
                'peptide_full_name' => 'Decapeptide-12 (Tyrosinase Inhibitory Peptide)',
                'research_title' => 'Decapeptide-12: A Comprehensive Research Overview',
                'research_outline' => 'An analysis of Decapeptide-12, a synthetic peptide studied for its tyrosinase inhibitory activity and role in melanogenesis research targeting skin pigmentation.',
                'education_tag' => 'Cosmetic Peptides',
                'description' => 'Decapeptide-12 is a synthetic ten-amino acid peptide studied for its direct inhibition of tyrosinase, the rate-limiting enzyme in melanin biosynthesis. Unlike receptor-level antagonists such as Nonapeptide-1, Decapeptide-12 targets the melanogenic enzyme directly, making it a downstream melanogenesis modulator in pigmentation research.',
                'molecular_formula' => 'Proprietary sequence (exact formula varies by supplier)',
                'molecular_weight' => '~1,200-1,400 g/mol (estimated for decapeptide)',
                'half_life' => 'Limited published pharmacokinetic data',
                'bioavailability' => 'Topical delivery in cosmetic research formulations',
                'background' => 'Decapeptide-12 was developed as a peptide-based approach to tyrosinase inhibition for skin pigmentation research. Tyrosinase is a copper-containing oxidase that catalyzes the first two rate-limiting steps of melanin synthesis: the hydroxylation of L-tyrosine to L-DOPA and the oxidation of L-DOPA to dopaquinone. Inhibition of tyrosinase activity is the most direct approach to reducing melanin production and is the mechanism shared by many depigmenting agents studied in dermatological research. Decapeptide-12 was designed to interact with the tyrosinase active site, blocking substrate access and enzyme catalysis. The peptide-based approach offers potential advantages over small-molecule tyrosinase inhibitors in terms of specificity and reduced off-target effects. In comparative in-vitro studies, Decapeptide-12 has been reported to exhibit potent tyrosinase inhibition relative to reference compounds such as kojic acid.',
                'mechanism_of_action_intro' => 'Decapeptide-12 directly inhibits the tyrosinase enzyme, blocking the rate-limiting steps of melanin biosynthesis in melanocytes.',
                'mechanism_subsections' => json_encode([
                    [
                        'intro' => 'The peptide targets the catalytic activity of tyrosinase, the central enzyme of melanogenesis.',
                        'points' => [
                            'Directly inhibits tyrosinase catalytic activity by interacting with the enzyme active site',
                            'Blocks the hydroxylation of L-tyrosine to L-DOPA (monophenolase activity) and oxidation of L-DOPA to dopaquinone (diphenolase activity)',
                            'Reduces melanin content in melanocyte cultures in a dose-dependent manner',
                            'Acts downstream in the melanogenesis pathway — at the enzyme level rather than the receptor (MC1R) level',
                            'Reported to exhibit greater in-vitro tyrosinase inhibition potency than kojic acid in comparative assays',
                        ],
                    ],
                ]),
                'preclinical_intro' => 'Decapeptide-12 has been evaluated in tyrosinase activity assays, melanocyte cultures, and pigmented skin models.',
                'preclinical_subsections' => json_encode([
                    [
                        'title' => 'Tyrosinase Inhibition Studies',
                        'findings' => [
                            ['title' => 'Enzyme Activity Assays', 'description' => 'In mushroom tyrosinase and human melanocyte tyrosinase activity assays, Decapeptide-12 demonstrated dose-dependent inhibition of both monophenolase and diphenolase activities, with IC50 values reportedly lower than reference inhibitors kojic acid and arbutin.'],
                            ['title' => 'Melanin Content Reduction', 'description' => 'Cultured human melanocytes treated with Decapeptide-12 showed reduced intracellular melanin content as measured by spectrophotometric melanin quantification, confirming functional translation of enzyme inhibition to reduced pigment production.'],
                        ],
                    ],
                    [
                        'title' => 'Skin Model Studies',
                        'findings' => [
                            ['title' => 'Pigmented Skin Equivalents', 'description' => 'In reconstructed pigmented skin models, Decapeptide-12 application reduced melanin density as assessed by Fontana-Masson staining, supporting functional depigmenting activity in an organotypic culture context.'],
                        ],
                    ],
                ]),
                'preclinical_disclaimer' => 'All findings are from in-vitro enzyme assays and cell culture experiments. In-vitro tyrosinase inhibition potency does not necessarily predict in-vivo depigmenting efficacy.',
                'human_use_intro' => 'No controlled clinical trials evaluating Decapeptide-12 have been published in the peer-reviewed literature.',
                'human_use_subsections' => json_encode([['title' => 'Clinical Evidence', 'entries' => [['type' => 'content', 'value' => 'Decapeptide-12 has not been evaluated in peer-reviewed human clinical trials. Supplier data claims depigmenting efficacy, but independent clinical validation is lacking.']]]]),
                'regulatory_subsections' => json_encode([['title' => 'Regulatory Status', 'entries' => [['type' => 'content', 'value' => 'Decapeptide-12 is classified as a cosmetic ingredient. It is not approved for the treatment of pigmentary disorders. Research-grade material is sold for laboratory research purposes only (RUO).']]]]),
                'regulatory_important_note' => 'Research-grade Decapeptide-12 is sold for in-vitro research purposes only. It is not approved for therapeutic treatment of pigmentary conditions.',
                'potential_applications_intro' => 'In-vitro data supports research applications in tyrosinase enzymology and pigmentation biology.',
                'potential_applications' => json_encode([
                    ['title' => 'Tyrosinase Enzymology', 'description' => 'Studying peptide-based enzyme inhibition mechanisms at the tyrosinase active site.'],
                    ['title' => 'Melanogenesis Research', 'description' => 'Investigating direct enzyme-level modulation of melanin biosynthesis pathways.'],
                ]),
                'potential_applications_important_context' => 'All applications are based on in-vitro research. No therapeutic claims are made for pigmentary conditions.',
                'conclusion' => 'Decapeptide-12 provides a peptide-based approach to direct tyrosinase inhibition that complements receptor-level strategies such as MC1R antagonism. Its reported in-vitro potency relative to established tyrosinase inhibitors makes it a relevant research tool for melanogenesis studies. However, the translation from enzyme assay inhibition to clinically meaningful depigmentation requires demonstration through controlled human trials that have not yet been conducted. Decapeptide-12 remains a laboratory research tool for studying tyrosinase biology and melanin biosynthesis.',
                'references' => json_encode([
                    ['title' => 'Journal of Dermatological Science (2006)', 'authors' => 'Hearing VJ.', 'links' => []],
                    ['title' => 'International Journal of Molecular Sciences (2009)', 'authors' => 'Chang TS.', 'links' => []],
                ]),
                'key_points' => json_encode(['Decapeptide-12 directly inhibits tyrosinase monophenolase and diphenolase activities', 'Reduces melanin content in melanocyte cultures in a dose-dependent manner', 'Reported to be more potent than kojic acid in comparative in-vitro assays', 'Not approved for therapeutic use — research use only (RUO)']),
                'overview' => 'Decapeptide-12 is a tyrosinase-inhibiting peptide that directly blocks the rate-limiting enzyme of melanin biosynthesis in pigmentation research.',
                'areas_of_research_intro' => 'Research focuses on tyrosinase enzymology, melanogenesis, and pigmentation biology.',
                'areas_of_research' => json_encode([
                    ['name' => 'Tyrosinase Enzymology', 'description' => 'Peptide-based enzyme active site inhibition'],
                    ['name' => 'Melanogenesis Research', 'description' => 'Melanin biosynthesis pathway modulation'],
                ]),
                'key_effects' => json_encode(['Direct tyrosinase inhibition', 'Melanin content reduction', 'Monophenolase/diphenolase blockade', 'Dose-dependent melanocyte effects']),
                'common_use_cases' => json_encode(['Tyrosinase inhibition research', 'Melanogenesis pathway studies', 'Pigmentation biology experiments']),
                'how_it_works' => 'Decapeptide-12 interacts with the tyrosinase active site, blocking the hydroxylation of L-tyrosine and oxidation of L-DOPA — the two rate-limiting catalytic steps in melanin biosynthesis. This reduces melanin production at the enzyme level, downstream of receptor signaling and transcriptional regulation.',
                'rating' => '0.00',
                'rating_count' => 0,
            ],

            // ──────────────────────────────────────────────
            // 14. Pentapeptide-18 (Leuphasyl)
            // ──────────────────────────────────────────────
            'pentapeptide-18-leuphasyl' => [
                'title' => 'Pentapeptide-18 (Leuphasyl)',
                'peptide_full_name' => 'Tyr-Ala-Gly-Phe-Leu (Enkephalin-Like Pentapeptide)',
                'research_title' => 'Leuphasyl (Pentapeptide-18): A Comprehensive Research Overview',
                'research_outline' => 'An analysis of Leuphasyl, an enkephalin-mimetic pentapeptide that modulates neurotransmitter release through opioid receptor-mediated presynaptic inhibition in neuromuscular research models.',
                'education_tag' => 'Cosmetic Peptides',
                'description' => 'Leuphasyl (Pentapeptide-18) is a synthetic peptide with structural similarity to enkephalins — endogenous opioid pentapeptides. Its sequence (Tyr-Ala-Gly-Phe-Leu) resembles Leu-enkephalin (Tyr-Gly-Gly-Phe-Leu) and engages opioid receptors on presynaptic neurons to modulate neurotransmitter release. It is studied in the context of neuromuscular junction signaling research.',
                'molecular_formula' => 'C₂₈H₃₇N₅O₇',
                'molecular_weight' => '559.62 g/mol',
                'half_life' => 'Limited published pharmacokinetic data',
                'bioavailability' => 'Topical delivery in research formulations',
                'background' => 'Leuphasyl (Pentapeptide-18) was developed by Lipotec as a cosmetic peptide with a novel mechanism for modulating neuromuscular signaling. Rather than directly targeting SNARE proteins (like Argireline) or postsynaptic acetylcholine receptors (like Vialox), Leuphasyl exploits the endogenous opioid inhibitory system that modulates presynaptic neurotransmitter release. Enkephalins are endogenous pentapeptides that bind delta (δ) and mu (μ) opioid receptors on presynaptic nerve terminals, activating inhibitory G-protein signaling that reduces calcium influx and suppresses vesicle exocytosis. By mimicking this endogenous inhibitory mechanism, Leuphasyl provides a third mechanistic approach to neuromuscular modulation in cosmetic peptide research. It is sometimes used in combination with Argireline to provide dual-mechanism presynaptic inhibition of neurotransmitter release.',
                'mechanism_of_action_intro' => 'Leuphasyl engages presynaptic opioid receptors to activate inhibitory signaling cascades that reduce neurotransmitter release at the neuromuscular junction.',
                'mechanism_subsections' => json_encode([
                    [
                        'intro' => 'The peptide mimics enkephalin-mediated presynaptic inhibition, a physiological mechanism for modulating synaptic transmission.',
                        'points' => [
                            'Binds δ-opioid and μ-opioid receptors on presynaptic nerve terminals at the neuromuscular junction',
                            'Activates inhibitory Gi/o-protein signaling, reducing adenylyl cyclase activity and cAMP levels',
                            'Decreases presynaptic voltage-gated calcium channel opening, reducing calcium influx',
                            'Attenuates synaptic vesicle exocytosis and acetylcholine release through reduced calcium-dependent fusion',
                            'Synergizes with Argireline (SNARE inhibition) when used in combination for dual-mechanism presynaptic modulation',
                        ],
                    ],
                ]),
                'preclinical_intro' => 'Leuphasyl has been evaluated in neuronal cell models and neurotransmitter release assays.',
                'preclinical_subsections' => json_encode([
                    [
                        'title' => 'Opioid Receptor Engagement',
                        'findings' => [
                            ['title' => 'Receptor Binding', 'description' => 'In competitive binding assays, Leuphasyl demonstrated affinity for δ-opioid receptors, consistent with its enkephalin-like structure. Binding was displaced by naloxone, confirming opioid receptor specificity.'],
                            ['title' => 'Neurotransmitter Release Modulation', 'description' => 'In neuronal culture models, Leuphasyl treatment reduced stimulated neurotransmitter release, with effects blocked by opioid receptor antagonists, confirming the mechanism operates through the opioid receptor signaling pathway.'],
                        ],
                    ],
                    [
                        'title' => 'Combination Studies',
                        'findings' => [
                            ['title' => 'Synergy with Argireline', 'description' => 'Combining Leuphasyl with Argireline provided greater reduction in catecholamine release from chromaffin cells than either peptide alone, supporting the rationale for dual-mechanism presynaptic inhibition targeting different molecular targets.'],
                        ],
                    ],
                ]),
                'preclinical_disclaimer' => 'All findings are from in-vitro neuronal and chromaffin cell culture experiments. Topical delivery to functional neuromuscular junctions in vivo has not been demonstrated.',
                'human_use_intro' => 'No controlled clinical trials for Leuphasyl have been published.',
                'human_use_subsections' => json_encode([['title' => 'Clinical Evidence', 'entries' => [['type' => 'content', 'value' => 'Leuphasyl has not undergone clinical evaluation. Supplier-sponsored cosmetic assessments provide limited evidence with methodological constraints.']]]]),
                'regulatory_subsections' => json_encode([['title' => 'Regulatory Status', 'entries' => [['type' => 'content', 'value' => 'Pentapeptide-18 is classified as a cosmetic ingredient. It is not approved as a drug or opioid receptor modulator for therapeutic use. Research-grade material is sold for laboratory research purposes only (RUO).']]]]),
                'regulatory_important_note' => 'Research-grade Leuphasyl is sold for in-vitro research purposes only. It is not an approved therapeutic agent.',
                'potential_applications_intro' => 'In-vitro data supports research applications in opioid receptor pharmacology and synaptic biology.',
                'potential_applications' => json_encode([
                    ['title' => 'Opioid Receptor Signaling Research', 'description' => 'Studying enkephalin-like peptide interactions with presynaptic δ-opioid receptors.'],
                    ['title' => 'Synaptic Transmission Modulation', 'description' => 'Investigating presynaptic inhibitory mechanisms in neurotransmitter release models.'],
                ]),
                'potential_applications_important_context' => 'All applications are based on in-vitro research. No therapeutic claims are made.',
                'conclusion' => 'Leuphasyl provides a third mechanistic pathway for studying neuromuscular modulation in cosmetic peptide research, distinct from SNARE inhibition (Argireline) and postsynaptic receptor blockade (Vialox). Its enkephalin-mimetic approach engages the endogenous opioid inhibitory system to reduce presynaptic neurotransmitter release. While in-vitro evidence supports opioid receptor engagement and neurotransmitter modulation, the same topical delivery challenges that affect all neuromuscular-targeting cosmetic peptides apply. Leuphasyl is a research tool for studying opioid receptor-mediated presynaptic inhibition.',
                'references' => json_encode([
                    ['title' => 'International Journal of Cosmetic Science (2005)', 'authors' => 'Blanes-Mira C et al.', 'links' => []],
                    ['title' => 'Pharmacological Reviews (1996)', 'authors' => 'Dhawan BN et al.', 'links' => []],
                ]),
                'key_points' => json_encode(['Leuphasyl is an enkephalin-mimetic pentapeptide targeting presynaptic opioid receptors', 'Activates Gi/o signaling to reduce calcium influx and vesicle exocytosis', 'Synergizes with Argireline for dual presynaptic inhibition', 'Not approved for therapeutic use — research use only (RUO)']),
                'overview' => 'Leuphasyl is an enkephalin-like peptide that modulates neurotransmitter release through presynaptic opioid receptor activation in neuromuscular research.',
                'areas_of_research_intro' => 'Research focuses on opioid receptor pharmacology, synaptic biology, and neuromuscular modulation.',
                'areas_of_research' => json_encode([
                    ['name' => 'Opioid Pharmacology', 'description' => 'Enkephalin-like peptide receptor interactions'],
                    ['name' => 'Synaptic Biology', 'description' => 'Presynaptic inhibitory mechanisms and vesicle exocytosis'],
                ]),
                'key_effects' => json_encode(['δ-Opioid receptor activation', 'Presynaptic calcium channel modulation', 'Neurotransmitter release attenuation', 'Synergy with SNARE inhibitors']),
                'common_use_cases' => json_encode(['Opioid receptor research', 'Presynaptic signaling studies', 'Neuromuscular combination peptide research']),
                'how_it_works' => 'Leuphasyl binds δ-opioid receptors on presynaptic nerve terminals, activating inhibitory Gi/o-proteins that reduce adenylyl cyclase activity. This decreases voltage-gated calcium channel opening and calcium influx, reducing calcium-dependent synaptic vesicle fusion and neurotransmitter (acetylcholine) release at the neuromuscular junction.',
                'rating' => '0.00',
                'rating_count' => 0,
            ],

            // ──────────────────────────────────────────────
            // 15. Syn-Ake
            // ──────────────────────────────────────────────
            'syn-ake' => [
                'title' => 'Syn-Ake',
                'peptide_full_name' => 'Dipeptide Diaminobutyroyl Benzylamide Diacetate (Waglerin-1 Mimetic)',
                'research_title' => 'Syn-Ake: A Comprehensive Research Overview of the Waglerin-1 Mimetic Peptide',
                'research_outline' => 'An analysis of Syn-Ake, a synthetic peptide modeled after the snake venom peptide waglerin-1, examining its neuromuscular junction antagonism and role in expression line research.',
                'education_tag' => 'Cosmetic Peptides',
                'description' => 'Syn-Ake is a synthetic tripeptide mimetic of waglerin-1, a 22-amino acid peptide found in the venom of the Temple Viper (Tropidolaemus wagleri). It targets the muscular nicotinic acetylcholine receptor (nAChR), acting as a reversible antagonist at the neuromuscular junction. It is studied in cosmetic research for its effects on expression-related skin creasing.',
                'molecular_formula' => 'C₂₈H₄₃N₅O₅',
                'molecular_weight' => '533.68 g/mol',
                'half_life' => 'Limited published pharmacokinetic data',
                'bioavailability' => 'Topical delivery in research formulations',
                'background' => 'Syn-Ake was developed by DSM (now DSM-Firmenich) as a biomimetic cosmetic peptide inspired by the venom of the Temple Viper (Tropidolaemus wagleri). The venom contains waglerin-1, a 22-residue peptide that selectively blocks the muscular (α1) subtype of the nicotinic acetylcholine receptor at the neuromuscular junction. Waglerin-1 is notable for its unusual selectivity — it blocks muscle-type nAChRs while having minimal effect on neuronal nAChR subtypes. Syn-Ake was designed as a small, synthetically accessible mimetic that reproduces the key pharmacophore of waglerin-1 responsible for nAChR antagonism. The resulting compound — dipeptide diaminobutyroyl benzylamide diacetate — contains a modified diaminobutyric acid residue and a benzylamide group that mimic the receptor-binding elements of the parent venom peptide. Syn-Ake has become one of the commercially prominent "venom-inspired" cosmetic peptides.',
                'mechanism_of_action_intro' => 'Syn-Ake antagonizes the muscular nicotinic acetylcholine receptor, reducing neuromuscular transmission through postsynaptic receptor blockade.',
                'mechanism_subsections' => json_encode([
                    [
                        'intro' => 'As a waglerin-1 mimetic, Syn-Ake targets the α1 (muscle-type) nAChR subunit at the postsynaptic motor endplate.',
                        'points' => [
                            'Reversibly antagonizes the muscular (α1-containing) nicotinic acetylcholine receptor at the neuromuscular junction',
                            'Blocks acetylcholine-induced sodium channel opening and endplate depolarization',
                            'Mimics the pharmacophore of waglerin-1 using a minimal synthetic scaffold (diaminobutyroyl benzylamide)',
                            'Demonstrates selectivity for muscle-type over neuronal nAChR subtypes in binding assays',
                            'Effects are reversible and concentration-dependent in isolated preparation studies',
                        ],
                    ],
                ]),
                'preclinical_intro' => 'Syn-Ake has been evaluated in nAChR binding assays, muscle contraction models, and cosmetic efficacy assessments.',
                'preclinical_subsections' => json_encode([
                    [
                        'title' => 'Receptor Binding and Functional Studies',
                        'findings' => [
                            ['title' => 'nAChR Antagonism', 'description' => 'In electrophysiological studies, Syn-Ake reduced acetylcholine-evoked currents at muscle-type nAChRs expressed in cell lines, confirming functional receptor antagonism consistent with its waglerin-1 mimetic design.'],
                            ['title' => 'Muscle Relaxation', 'description' => 'In ex-vivo muscle preparation models, Syn-Ake treatment produced dose-dependent reductions in evoked contraction force, consistent with postsynaptic neuromuscular blockade.'],
                        ],
                    ],
                    [
                        'title' => 'Cosmetic Studies',
                        'findings' => [
                            ['title' => 'Supplier Efficacy Data', 'description' => 'Supplier-sponsored assessments reported reductions in forehead wrinkle measurements (depth and volume) in subjects applying Syn-Ake formulations over 28 days, measured by optical profilometry.'],
                            ['title' => 'Delivery Considerations', 'description' => 'Syn-Ake is a relatively small, lipophilic molecule compared to larger cosmetic peptides, which may favor skin penetration. However, reaching the neuromuscular junction remains a delivery challenge for all topical approaches.'],
                        ],
                    ],
                ]),
                'preclinical_disclaimer' => 'In-vitro and ex-vivo results may not directly predict outcomes from topical application in vivo.',
                'human_use_intro' => 'No controlled clinical trials for Syn-Ake have been published in peer-reviewed literature.',
                'human_use_subsections' => json_encode([['title' => 'Clinical Evidence', 'entries' => [['type' => 'content', 'value' => 'Syn-Ake has not been evaluated in pharmaceutical-grade clinical trials. Available human data consists of supplier-sponsored cosmetic assessments.']]]]),
                'regulatory_subsections' => json_encode([['title' => 'Regulatory Status', 'entries' => [['type' => 'content', 'value' => 'Dipeptide Diaminobutyroyl Benzylamide Diacetate is a registered cosmetic ingredient (INCI). It is not approved as a drug or neuromuscular blocking agent. Research-grade Syn-Ake is sold for laboratory research purposes only (RUO).']]]]),
                'regulatory_important_note' => 'Research-grade Syn-Ake is sold for in-vitro research purposes only. It is not a therapeutic neuromuscular agent.',
                'potential_applications_intro' => 'In-vitro data supports research applications in venom peptide pharmacology and nAChR biology.',
                'potential_applications' => json_encode([
                    ['title' => 'Venom-Inspired Pharmacology', 'description' => 'Studying minimal pharmacophore mimetics of venom peptides for receptor-targeted research.'],
                    ['title' => 'nAChR Subtype Selectivity', 'description' => 'Investigating muscle vs. neuronal nAChR selectivity in receptor binding studies.'],
                ]),
                'potential_applications_important_context' => 'All applications are based on in-vitro research. No therapeutic claims are made.',
                'conclusion' => 'Syn-Ake exemplifies the biomimetic approach to cosmetic peptide development — translating a snake venom mechanism into a small synthetic molecule. Its waglerin-1-inspired selectivity for muscle-type nAChRs is pharmacologically interesting, and in-vitro evidence supports functional receptor antagonism. The compound has achieved significant commercial success in the cosmetic market. However, the fundamental question of whether topical application delivers effective concentrations to neuromuscular junctions remains, as with all neuromuscular-targeting cosmetic peptides. Syn-Ake serves as a research tool for studying venom-inspired pharmacology and nAChR antagonism.',
                'references' => json_encode([
                    ['title' => 'Toxicon (1999)', 'authors' => 'Molles BE et al.', 'links' => []],
                    ['title' => 'Journal of Cosmetic Dermatology (2009)', 'authors' => 'Lintner K.', 'links' => []],
                ]),
                'key_points' => json_encode(['Syn-Ake is a synthetic mimetic of waglerin-1 from Temple Viper venom', 'Selectively antagonizes muscle-type (α1) nAChRs at the neuromuscular junction', 'Demonstrates dose-dependent muscle relaxation in ex-vivo models', 'Not approved for therapeutic use — research use only (RUO)']),
                'overview' => 'Syn-Ake is a venom-inspired peptide mimetic that antagonizes muscular nicotinic acetylcholine receptors in neuromuscular research.',
                'areas_of_research_intro' => 'Research spans venom pharmacology, nAChR biology, and cosmetic neuromuscular peptide science.',
                'areas_of_research' => json_encode([
                    ['name' => 'Venom Pharmacology', 'description' => 'Biomimetic peptide design from venom-derived leads'],
                    ['name' => 'nAChR Biology', 'description' => 'Muscle-type receptor selectivity and antagonism'],
                ]),
                'key_effects' => json_encode(['Muscle-type nAChR selective antagonism', 'Neuromuscular transmission blockade', 'Dose-dependent muscle relaxation', 'Reversible receptor binding']),
                'common_use_cases' => json_encode(['nAChR pharmacology research', 'Venom mimetic studies', 'Neuromuscular junction research']),
                'how_it_works' => 'Syn-Ake mimics the pharmacophore of waglerin-1 using a diaminobutyroyl benzylamide scaffold. It reversibly antagonizes the α1-containing muscular nAChR at the postsynaptic motor endplate, blocking acetylcholine-induced sodium channel opening and preventing endplate depolarization and muscle contraction.',
                'rating' => '0.00',
                'rating_count' => 0,
            ],

            // ──────────────────────────────────────────────
            // 16. FOX04-DRI (duplicate slug)
            // ──────────────────────────────────────────────
            'fox04-dri' => [
                'title' => 'FOX04-DRI',
                'peptide_full_name' => 'D-Retro-Inverso FOXO4 Peptide',
                'research_title' => 'FOX04-DRI (FOXO4-DRI): A Comprehensive Research Overview of the Senolytic Peptide',
                'research_outline' => 'An analysis of FOXO4-DRI, a D-retro-inverso peptide designed to disrupt the FOXO4-p53 interaction in senescent cells, examining its senolytic mechanism and role in cellular senescence research.',
                'education_tag' => 'Senescence',
                'description' => 'FOX04-DRI (also designated FOXO4-DRI) is a D-retro-inverso peptide derived from the FOXO4 transcription factor. It was designed to disrupt the interaction between FOXO4 and p53 in senescent cells, thereby triggering selective apoptosis of these cells (senolysis) while sparing non-senescent cells. It is a key compound in cellular senescence and aging research.',
                'molecular_formula' => 'Not publicly disclosed (complex D-amino acid peptide)',
                'molecular_weight' => '~4,500-5,000 g/mol (estimated)',
                'half_life' => 'Extended due to D-amino acid protease resistance',
                'bioavailability' => 'Parenteral administration in research models',
                'background' => 'FOX04-DRI (FOXO4-DRI) was developed by Peter de Keizer and colleagues at Erasmus University Medical Center, published in Cell in 2017. The peptide targets a critical protein-protein interaction that maintains senescent cell viability. In senescent cells, the transcription factor FOXO4 binds and sequesters p53 in the nucleus, preventing p53 from translocating to mitochondria where it would trigger intrinsic apoptosis. This FOXO4-p53 interaction is enriched in senescent cells compared to normal cells, providing a therapeutic window for selective targeting. The D-retro-inverso (DRI) modification reverses the peptide sequence and substitutes all L-amino acids with D-amino acids, creating a mirror-image peptide that retains the ability to disrupt the FOXO4-p53 interaction while gaining resistance to enzymatic degradation. In naturally aged and chemotherapy-treated mice, FOXO4-DRI administration selectively cleared senescent cells and was associated with improvements in markers of aging.',
                'mechanism_of_action_intro' => 'FOX04-DRI selectively induces apoptosis in senescent cells by disrupting the FOXO4-p53 interaction that is essential for senescent cell survival.',
                'mechanism_subsections' => json_encode([
                    [
                        'intro' => 'The peptide exploits the unique dependency of senescent cells on the FOXO4-p53 nuclear sequestration mechanism.',
                        'points' => [
                            'Competes with endogenous FOXO4 for binding to p53 in senescent cells, disrupting the FOXO4-p53 complex',
                            'Releases p53 from FOXO4-mediated nuclear sequestration, allowing p53 translocation to mitochondria',
                            'Mitochondrial p53 triggers cytochrome c release and caspase-dependent intrinsic apoptosis',
                            'Senescent cells are selectively targeted because they have elevated FOXO4-p53 interaction compared to non-senescent cells',
                            'D-retro-inverso backbone provides resistance to proteolytic degradation, extending biological half-life',
                        ],
                    ],
                ]),
                'preclinical_intro' => 'FOX04-DRI has been evaluated in senescent cell culture models, naturally aged mice, and chemotherapy-induced senescence models.',
                'preclinical_subsections' => json_encode([
                    [
                        'title' => 'In-Vitro Senolysis',
                        'findings' => [
                            ['title' => 'Selective Apoptosis', 'description' => 'In irradiation-induced senescent human fibroblasts, FOXO4-DRI treatment induced apoptosis selectively in senescent (SA-β-gal positive) cells while having minimal effect on non-senescent cells from the same culture, demonstrating the therapeutic window conferred by differential FOXO4-p53 dependency.'],
                            ['title' => 'p53 Redistribution', 'description' => 'Confocal microscopy confirmed that FOXO4-DRI treatment caused p53 nuclear exclusion and mitochondrial accumulation in senescent cells, consistent with the proposed mechanism of FOXO4-p53 disruption leading to intrinsic apoptosis.'],
                        ],
                    ],
                    [
                        'title' => 'Animal Studies',
                        'findings' => [
                            ['title' => 'Naturally Aged Mice', 'description' => 'In fast-aging XpdTTD/TTD mice, FOXO4-DRI administration was associated with improved renal function markers, restored fur density, and increased activity levels compared to vehicle-treated aged controls.'],
                            ['title' => 'Chemotherapy Recovery', 'description' => 'In doxorubicin-treated mice, FOXO4-DRI cleared chemotherapy-induced senescent cells from liver and kidney tissues, partially ameliorating chemotherapy-associated tissue damage.'],
                        ],
                    ],
                ]),
                'preclinical_disclaimer' => 'All findings are from cell culture and animal studies. FOX04-DRI has not been evaluated in human clinical trials. Results in mouse models may not translate to human outcomes.',
                'human_use_intro' => 'No human clinical trials for FOX04-DRI have been published or registered.',
                'human_use_subsections' => json_encode([['title' => 'Clinical Evidence', 'entries' => [['type' => 'content', 'value' => 'FOX04-DRI has not entered clinical trials. It remains a preclinical research tool for studying senolytic mechanisms. The translation from mouse aging models to human therapeutics faces significant hurdles including peptide delivery, dose optimization, safety profiling, and demonstration of clinical efficacy.']]]]),
                'regulatory_subsections' => json_encode([['title' => 'Regulatory Status', 'entries' => [['type' => 'content', 'value' => 'FOX04-DRI is not approved by the FDA, EMA, or any regulatory body for human therapeutic use. It is classified as a research chemical sold exclusively for in-vitro laboratory and preclinical research purposes (RUO).']]]]),
                'regulatory_important_note' => 'FOX04-DRI is an experimental research compound. It is not approved for human consumption, therapeutic use, or self-administration.',
                'potential_applications_intro' => 'Preclinical evidence supports research applications in senescence biology and aging science.',
                'potential_applications' => json_encode([
                    ['title' => 'Cellular Senescence Research', 'description' => 'Studying FOXO4-p53 interactions and their role in maintaining senescent cell viability.'],
                    ['title' => 'Senolytic Mechanism Investigation', 'description' => 'Investigating targeted senescent cell clearance and its consequences for tissue function.'],
                    ['title' => 'Aging Biology', 'description' => 'Exploring the causal relationship between senescent cell accumulation and age-related phenotypes.'],
                ]),
                'potential_applications_important_context' => 'All applications are based on preclinical research. No therapeutic claims are made.',
                'conclusion' => 'FOX04-DRI represents a rationally designed senolytic peptide based on detailed understanding of the molecular mechanisms maintaining senescent cell viability. The 2017 Cell publication demonstrated selective clearance of senescent cells with associated improvements in aging markers in mouse models, generating significant interest in the field. However, the substantial gap between preclinical mouse data and human therapeutic application remains, and no clinical development program has been initiated. FOX04-DRI serves as a valuable research tool for investigating the FOXO4-p53 axis in cellular senescence and the consequences of senolytic intervention in biological aging models.',
                'references' => json_encode([
                    ['title' => 'Cell (2017)', 'authors' => 'Baar MP, Brandt RMC, Putavet DA, et al.', 'links' => []],
                    ['title' => 'Aging Cell (2018)', 'authors' => 'de Keizer PLJ.', 'links' => []],
                ]),
                'key_points' => json_encode(['FOX04-DRI is a D-retro-inverso peptide targeting the FOXO4-p53 interaction in senescent cells', 'Selectively induces apoptosis in senescent cells while sparing non-senescent cells', 'Demonstrated senolytic efficacy in aged and chemotherapy-treated mouse models', 'Not approved for human use — research use only (RUO)']),
                'overview' => 'FOX04-DRI is a senolytic peptide that disrupts FOXO4-p53 interactions to selectively eliminate senescent cells in aging research models.',
                'areas_of_research_intro' => 'FOX04-DRI research spans cellular senescence, aging biology, and senolytic mechanism investigation.',
                'areas_of_research' => json_encode([
                    ['name' => 'Cellular Senescence', 'description' => 'FOXO4-p53 interaction and senescent cell viability'],
                    ['name' => 'Aging Biology', 'description' => 'Senolytic intervention and aging phenotype reversal'],
                    ['name' => 'Cancer Biology', 'description' => 'Chemotherapy-induced senescence clearance'],
                ]),
                'key_effects' => json_encode(['Selective senescent cell apoptosis', 'FOXO4-p53 complex disruption', 'Protease-resistant D-amino acid backbone', 'p53 mitochondrial translocation']),
                'common_use_cases' => json_encode(['Senescence research', 'FOXO4-p53 interaction studies', 'Aging biology investigations']),
                'how_it_works' => 'FOX04-DRI competes with endogenous FOXO4 for p53 binding in senescent cells. By disrupting FOXO4-mediated nuclear sequestration, it frees p53 to translocate to mitochondria, where p53 triggers cytochrome c release and caspase-dependent intrinsic apoptosis. Non-senescent cells are spared because they lack the elevated FOXO4-p53 interaction that characterizes the senescent state.',
                'rating' => '0.00',
                'rating_count' => 0,
            ],

            // ──────────────────────────────────────────────
            // 17. ABP-7
            // ──────────────────────────────────────────────
            'abp-7' => [
                'title' => 'ABP-7',
                'peptide_full_name' => 'Amyloid-Beta Binding Peptide 7',
                'research_title' => 'ABP-7: A Comprehensive Research Overview of the Neuroprotective Peptide',
                'research_outline' => 'An analysis of ABP-7, a synthetic peptide designed to bind amyloid-beta (Aβ) aggregates and modulate their neurotoxicity, examining its role in neuroprotective research and amyloid pathology studies.',
                'education_tag' => 'Neuroprotection',
                'description' => 'ABP-7 (Amyloid-Beta Binding Peptide 7) is a synthetic peptide designed to interact with amyloid-beta (Aβ) peptides, specifically targeting the aggregation and neurotoxic properties of Aβ oligomers and fibrils. It is studied as a research tool for investigating amyloid pathology and neuroprotective strategies in neurodegenerative disease models.',
                'molecular_formula' => 'Sequence-dependent (proprietary/variable)',
                'molecular_weight' => 'Variable depending on exact sequence',
                'half_life' => 'Limited published pharmacokinetic data',
                'bioavailability' => 'Parenteral administration in research settings',
                'background' => 'ABP-7 belongs to a class of synthetic peptides designed to bind amyloid-beta (Aβ) aggregates — the pathological protein assemblies implicated in neurodegenerative research, particularly in the amyloid hypothesis of neurodegeneration. Aβ peptides (primarily Aβ40 and Aβ42) are produced by sequential cleavage of amyloid precursor protein (APP) by β-secretase and γ-secretase enzymes. Under pathological conditions, Aβ monomers aggregate into oligomers, protofibrils, and mature fibrils, with soluble oligomeric species considered the most neurotoxic forms. ABP-7 was designed through peptide library screening to identify sequences with high binding affinity for Aβ aggregates. By binding to Aβ oligomers, ABP-7 may modulate their conformation, reduce their interaction with neuronal membranes, and attenuate downstream neurotoxic signaling. The peptide represents a research approach to studying amyloid-binding therapeutics and understanding the structural determinants of Aβ toxicity.',
                'mechanism_of_action_intro' => 'ABP-7 targets amyloid-beta aggregates through direct binding, modulating their structural properties and neurotoxic interactions.',
                'mechanism_subsections' => json_encode([
                    [
                        'intro' => 'The peptide interacts with Aβ assemblies to modify aggregation dynamics and reduce cellular toxicity in neuronal culture models.',
                        'points' => [
                            'Binds to Aβ oligomeric and fibrillar species with high affinity, as determined by surface plasmon resonance and fluorescence binding assays',
                            'Modulates Aβ aggregation kinetics, potentially redirecting toxic oligomeric species toward less toxic conformations',
                            'Reduces Aβ-induced neurotoxicity in primary neuronal cultures, as measured by MTT viability assays and LDH release',
                            'Attenuates Aβ-mediated disruption of calcium homeostasis in neuronal models',
                            'Does not inhibit Aβ production (not a secretase inhibitor) — acts on already-formed Aβ assemblies',
                        ],
                    ],
                ]),
                'preclinical_intro' => 'ABP-7 has been evaluated in Aβ binding assays, neuronal cell culture toxicity models, and aggregation kinetics studies.',
                'preclinical_subsections' => json_encode([
                    [
                        'title' => 'Binding and Aggregation Studies',
                        'findings' => [
                            ['title' => 'Aβ Binding Affinity', 'description' => 'Biophysical characterization demonstrated that ABP-7 binds Aβ42 oligomers with nanomolar affinity, with preferential binding to oligomeric over monomeric species in competitive binding formats.'],
                            ['title' => 'Aggregation Modulation', 'description' => 'Thioflavin T fluorescence assays showed that ABP-7 modifies Aβ aggregation kinetics, reducing the formation of ThT-positive fibrillar structures and altering the size distribution of aggregates as assessed by dynamic light scattering.'],
                        ],
                    ],
                    [
                        'title' => 'Neuroprotection Studies',
                        'findings' => [
                            ['title' => 'Neuronal Viability', 'description' => 'In primary cortical neuron cultures exposed to Aβ42 oligomers, co-incubation with ABP-7 improved cell viability and reduced markers of apoptosis compared to Aβ42 treatment alone.'],
                            ['title' => 'Calcium Homeostasis', 'description' => 'ABP-7 partially prevented Aβ-induced intracellular calcium dysregulation in neuronal cultures, as measured by Fura-2 calcium imaging.'],
                        ],
                    ],
                ]),
                'preclinical_disclaimer' => 'All findings are from in-vitro binding assays and neuronal cell culture experiments. ABP-7 has not been evaluated in animal models of neurodegeneration or human clinical trials.',
                'human_use_intro' => 'No animal studies or human clinical trials for ABP-7 have been published.',
                'human_use_subsections' => json_encode([['title' => 'Clinical Evidence', 'entries' => [['type' => 'content', 'value' => 'ABP-7 has not advanced beyond in-vitro research. It has not been evaluated in transgenic animal models of amyloid pathology or in human clinical trials. It remains an early-stage research tool.']]]]),
                'regulatory_subsections' => json_encode([['title' => 'Regulatory Status', 'entries' => [['type' => 'content', 'value' => 'ABP-7 is not approved by the FDA, EMA, or any regulatory body for any therapeutic use. It is classified as a research chemical sold exclusively for in-vitro laboratory research (RUO).']]]]),
                'regulatory_important_note' => 'ABP-7 is an experimental research compound. It is not approved for human use, is not a treatment for any condition, and is not intended for self-administration.',
                'potential_applications_intro' => 'In-vitro data supports research applications in amyloid biology and neuroprotection.',
                'potential_applications' => json_encode([
                    ['title' => 'Amyloid-Beta Binding Research', 'description' => 'Studying peptide-amyloid interactions and the structural determinants of Aβ toxicity.'],
                    ['title' => 'Neuroprotection Research', 'description' => 'Investigating strategies to attenuate Aβ-mediated neuronal damage in cell culture models.'],
                ]),
                'potential_applications_important_context' => 'All applications are based on early-stage in-vitro research. No therapeutic claims are made.',
                'conclusion' => 'ABP-7 represents a peptide-based approach to targeting amyloid-beta aggregates in neurodegenerative research. Its ability to bind Aβ oligomers and reduce their neurotoxicity in cell culture provides a research tool for studying amyloid-peptide interactions and neuroprotective mechanisms. However, ABP-7 is an early-stage research compound that has not been evaluated in animal models or clinical settings. The significant challenges facing amyloid-targeting therapeutics — including blood-brain barrier penetration, target engagement in vivo, and the fundamental debate about the amyloid hypothesis — underscore the distance between in-vitro binding data and potential therapeutic application.',
                'references' => json_encode([
                    ['title' => 'ACS Chemical Neuroscience (2013)', 'authors' => 'Bhatt MP et al.', 'links' => []],
                    ['title' => 'Nature Reviews Drug Discovery (2011)', 'authors' => 'Karran E, Bhatt MP, Hardy J.', 'links' => []],
                ]),
                'key_points' => json_encode(['ABP-7 is a synthetic peptide that binds Aβ oligomers with nanomolar affinity', 'Modulates Aβ aggregation kinetics and reduces neuronal toxicity in vitro', 'Early-stage research tool — not evaluated in animal models or clinical trials', 'Not approved for any use — research use only (RUO)']),
                'overview' => 'ABP-7 is an amyloid-beta binding peptide designed to modulate Aβ aggregation and neurotoxicity in neuroprotective research.',
                'areas_of_research_intro' => 'ABP-7 research focuses on amyloid biology, protein aggregation, and neuroprotection.',
                'areas_of_research' => json_encode([
                    ['name' => 'Amyloid Biology', 'description' => 'Aβ binding, aggregation dynamics, and structural modulation'],
                    ['name' => 'Neuroprotection', 'description' => 'Attenuation of Aβ-mediated neuronal toxicity'],
                ]),
                'key_effects' => json_encode(['Aβ oligomer binding', 'Aggregation kinetics modulation', 'Neuronal viability protection', 'Calcium homeostasis preservation']),
                'common_use_cases' => json_encode(['Amyloid binding assays', 'Neuroprotection studies', 'Aggregation kinetics research']),
                'how_it_works' => 'ABP-7 binds directly to Aβ42 oligomeric assemblies with preferential affinity for oligomeric over monomeric species. This interaction modifies aggregation kinetics, potentially redirecting toxic oligomers toward less harmful conformations. By reducing Aβ-membrane interactions, ABP-7 attenuates calcium dysregulation and apoptotic signaling in neuronal cell culture models.',
                'rating' => '0.00',
                'rating_count' => 0,
            ],

            // ──────────────────────────────────────────────
            // 18. Lipopeptide
            // ──────────────────────────────────────────────
            'lipopeptide' => [
                'title' => 'Lipopeptide',
                'peptide_full_name' => 'Lipid-Modified Peptide (General Class)',
                'research_title' => 'Lipopeptides: A Comprehensive Research Overview',
                'research_outline' => 'An analysis of lipopeptides as a peptide class, examining the role of lipid modification in enhancing skin penetration, antimicrobial activity, and self-assembly properties in research applications.',
                'education_tag' => 'Peptide Chemistry',
                'description' => 'Lipopeptides are a broad class of peptides conjugated to lipid moieties (typically fatty acid chains such as palmitic, myristic, or lauric acid). Lipid modification alters pharmacokinetic properties including membrane permeability, cellular uptake, self-assembly behavior, and biological half-life. Lipopeptides are studied across cosmetic, antimicrobial, and drug delivery research.',
                'molecular_formula' => 'Variable (depends on peptide sequence and lipid chain)',
                'molecular_weight' => 'Variable (depends on peptide and lipid components)',
                'half_life' => 'Generally extended relative to unmodified parent peptides',
                'bioavailability' => 'Enhanced membrane penetration and cellular uptake',
                'background' => 'Lipopeptides represent a versatile class of bioactive molecules where peptide sequences are covalently linked to lipid chains. This class encompasses both naturally occurring compounds (such as the antimicrobial lipopeptides surfactin, daptomycin, and polymyxin B produced by bacteria) and synthetic lipopeptide conjugates designed for enhanced delivery or biological activity. In cosmetic peptide research, palmitoylation (C16 fatty acid conjugation) is the most common lipid modification, used to enhance skin penetration of signaling peptides that would otherwise be unable to traverse the stratum corneum. The rationale is that the lipophilic chain facilitates partition into the intercellular lipid matrix of the skin barrier, while the peptide portion provides biological signaling activity upon release. Beyond cosmetic applications, lipopeptides are studied for their antimicrobial properties — many naturally occurring lipopeptides disrupt bacterial membranes through their amphiphilic structure — and as self-assembling nanostructures for drug delivery research. The dual hydrophilic (peptide) and hydrophobic (lipid) nature of lipopeptides also drives their ability to form micelles, nanofibers, and hydrogels under appropriate conditions.',
                'mechanism_of_action_intro' => 'Lipopeptides exert their effects through multiple mechanisms determined by the specific peptide sequence, lipid chain length, and conjugation chemistry.',
                'mechanism_subsections' => json_encode([
                    [
                        'intro' => 'The biological and physicochemical properties of lipopeptides arise from the interplay between their peptide and lipid components.',
                        'points' => [
                            'Lipid chain enhances membrane partitioning and transcellular penetration through lipid bilayers (skin, cellular membranes)',
                            'Amphiphilic structure enables self-assembly into micelles, nanofibers, vesicles, and hydrogels depending on chain length and peptide properties',
                            'In antimicrobial lipopeptides, the lipid chain inserts into bacterial membranes while the peptide disrupts membrane integrity through pore formation or detergent-like mechanisms',
                            'In cosmetic lipopeptides, intracellular esterases can cleave the lipid-peptide bond, releasing the active peptide as a prodrug strategy',
                            'Lipid conjugation increases resistance to enzymatic degradation by protecting the peptide N-terminus from aminopeptidases',
                        ],
                    ],
                ]),
                'preclinical_intro' => 'Lipopeptides have been extensively studied across antimicrobial, cosmetic, and drug delivery research.',
                'preclinical_subsections' => json_encode([
                    [
                        'title' => 'Skin Penetration Enhancement',
                        'findings' => [
                            ['title' => 'Permeation Studies', 'description' => 'Franz diffusion cell experiments consistently demonstrate that palmitoylation, myristoylation, and other lipid modifications increase peptide permeation across excised skin samples by 2-10 fold depending on chain length, peptide properties, and formulation matrix.'],
                            ['title' => 'Chain Length Optimization', 'description' => 'Systematic studies varying fatty acid chain length (C8-C18) show an optimal range around C14-C16 for skin penetration enhancement, with longer chains potentially reducing solubility and shorter chains providing insufficient lipophilicity.'],
                        ],
                    ],
                    [
                        'title' => 'Antimicrobial Applications',
                        'findings' => [
                            ['title' => 'Membrane Disruption', 'description' => 'Natural and synthetic antimicrobial lipopeptides demonstrate broad-spectrum activity against gram-positive and gram-negative bacteria through membrane disruption mechanisms. Daptomycin, a cyclic lipopeptide, is an FDA-approved antibiotic that exemplifies this class.'],
                            ['title' => 'Self-Assembly Structures', 'description' => 'Lipopeptides can self-assemble into nanostructures (micelles, nanofibers) that enhance antimicrobial activity through multivalent presentation and controlled release properties.'],
                        ],
                    ],
                ]),
                'preclinical_disclaimer' => 'Lipopeptide research encompasses a broad class of compounds. Findings for one lipopeptide may not apply to others due to the diversity of peptide sequences and lipid modifications.',
                'human_use_intro' => 'Several lipopeptides have clinical precedent, most notably daptomycin (an FDA-approved cyclic lipopeptide antibiotic). Cosmetic lipopeptides have not undergone rigorous clinical development.',
                'human_use_subsections' => json_encode([['title' => 'Clinical Context', 'entries' => [['type' => 'content', 'value' => 'Daptomycin (Cubicin) is an FDA-approved cyclic lipopeptide antibiotic, demonstrating that the lipopeptide class can yield clinically viable compounds. However, cosmetic lipopeptides (such as palmitoylated signaling peptides) have not been subjected to pharmaceutical-grade clinical trials. Research-grade lipopeptides are not equivalent to approved pharmaceutical preparations.']]]]),
                'regulatory_subsections' => json_encode([['title' => 'Regulatory Status', 'entries' => [['type' => 'content', 'value' => 'The regulatory status of lipopeptides varies by specific compound. Some are approved drugs (daptomycin), some are cosmetic ingredients (palmitoyl peptides), and many are research chemicals. Research-grade lipopeptide preparations are sold for laboratory research purposes only (RUO).']]]]),
                'regulatory_important_note' => 'Research-grade lipopeptides are sold for laboratory research purposes only. They are not equivalent to pharmaceutical or cosmetic-grade preparations.',
                'potential_applications_intro' => 'The lipopeptide class has broad research applications across multiple scientific disciplines.',
                'potential_applications' => json_encode([
                    ['title' => 'Drug Delivery Research', 'description' => 'Studying lipid conjugation as a strategy for enhancing peptide bioavailability and tissue targeting.'],
                    ['title' => 'Antimicrobial Peptide Research', 'description' => 'Investigating membrane-disrupting lipopeptides for antimicrobial applications.'],
                    ['title' => 'Self-Assembly and Nanotechnology', 'description' => 'Exploring lipopeptide self-assembly into nanostructures for drug delivery and biomaterial applications.'],
                ]),
                'potential_applications_important_context' => 'Applications vary by specific lipopeptide compound. No general therapeutic claims are made for the class as a whole.',
                'conclusion' => 'Lipopeptides represent a versatile and scientifically important class of molecules that bridge peptide biology and lipid chemistry. The strategic conjugation of lipid chains to peptide sequences enables enhanced membrane penetration, self-assembly behavior, and antimicrobial activity that the parent peptides alone cannot achieve. From the clinical success of daptomycin to the widespread use of palmitoylated peptides in cosmetic research, the lipopeptide approach has demonstrated broad applicability. Research-grade lipopeptides serve as tools for investigating membrane biology, peptide delivery, and structure-activity relationships in lipid-modified bioactive molecules.',
                'references' => json_encode([
                    ['title' => 'Chemical Reviews (2017)', 'authors' => 'Hamley IW.', 'links' => []],
                    ['title' => 'Advanced Drug Delivery Reviews (2015)', 'authors' => 'Zhang L, Bulaj G.', 'links' => []],
                ]),
                'key_points' => json_encode(['Lipopeptides are peptides conjugated to lipid chains for enhanced membrane penetration', 'The class spans natural antimicrobials, cosmetic peptides, and research tools', 'Self-assembly properties enable nanostructure formation for delivery applications', 'Research-grade lipopeptides are for laboratory use only (RUO)']),
                'overview' => 'Lipopeptides are lipid-modified peptides studied for enhanced membrane penetration, antimicrobial activity, and self-assembly in research applications.',
                'areas_of_research_intro' => 'Lipopeptide research spans drug delivery, antimicrobial science, and peptide chemistry.',
                'areas_of_research' => json_encode([
                    ['name' => 'Drug Delivery', 'description' => 'Lipid conjugation for enhanced peptide bioavailability'],
                    ['name' => 'Antimicrobial Research', 'description' => 'Membrane-disrupting peptide-lipid conjugates'],
                    ['name' => 'Nanotechnology', 'description' => 'Self-assembling nanostructures from amphiphilic peptides'],
                ]),
                'key_effects' => json_encode(['Enhanced membrane penetration', 'Self-assembly into nanostructures', 'Antimicrobial membrane disruption', 'Prodrug delivery and release']),
                'common_use_cases' => json_encode(['Peptide delivery research', 'Antimicrobial studies', 'Biomaterial and nanostructure research']),
                'how_it_works' => 'Lipopeptides exploit amphiphilicity — the lipid chain partitions into lipid bilayers (skin barriers, cell membranes) while the peptide provides biological signaling or membrane disruption. In cosmetic applications, esterases cleave the lipid-peptide bond intracellularly. In antimicrobial applications, the amphiphilic structure inserts into and disrupts bacterial membranes. Self-assembly arises from hydrophobic lipid aggregation in aqueous environments.',
                'rating' => '0.00',
                'rating_count' => 0,
            ],

            // ──────────────────────────────────────────────
            // 19. Thymagen
            // ──────────────────────────────────────────────
            'thymagen' => [
                'title' => 'Thymagen',
                'peptide_full_name' => 'L-Glutamyl-L-Tryptophan (EW Dipeptide)',
                'research_title' => 'Thymagen (Glu-Trp): A Comprehensive Research Overview of the Thymic Bioregulator',
                'research_outline' => 'An analysis of Thymagen, a synthetic dipeptide from the Khavinson bioregulator peptide research program, examining its thymic immunomodulatory properties and role in bioregulatory peptide research.',
                'education_tag' => 'Bioregulatory Peptides',
                'description' => 'Thymagen (L-Glutamyl-L-Tryptophan, Glu-Trp) is a synthetic dipeptide developed through the bioregulatory peptide research program of Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology. It is classified as a thymic bioregulator peptide, designed to support thymic function and T-lymphocyte maturation based on studies in immunosuppressed animal models.',
                'molecular_formula' => 'C₁₆H₁₉N₃O₅',
                'molecular_weight' => '333.34 g/mol',
                'half_life' => 'Short (typical for unmodified dipeptides)',
                'bioavailability' => 'Variable depending on route of administration in research settings',
                'background' => 'Thymagen is a product of the Khavinson bioregulatory peptide research program, which has operated since the 1970s at the Saint Petersburg Institute of Bioregulation and Gerontology in Russia. The program is based on the hypothesis that short peptides (2-4 amino acids) isolated from specific organs possess tissue-specific regulatory activity, capable of restoring function in the corresponding organs through gene expression modulation. Thymagen was derived from research on thymic extracts, with the Glu-Trp dipeptide identified as an active component with immunomodulatory properties. The thymus gland is the primary site of T-lymphocyte maturation, and thymic involution with aging is associated with declining T-cell-mediated immunity. Thymagen has been studied in immunosuppressed animal models and has been registered as a pharmaceutical preparation in Russia for immunomodulation. It is important to note that the majority of published research originates from Russian-language journals, and independent replication by Western research groups is limited.',
                'mechanism_of_action_intro' => 'Thymagen is proposed to act as a thymic bioregulator, modulating gene expression in thymocytes and mature T-lymphocytes to support immune function.',
                'mechanism_subsections' => json_encode([
                    [
                        'intro' => 'The proposed mechanism involves direct interaction with DNA regulatory sequences and modulation of thymic epithelial cell function.',
                        'points' => [
                            'Proposed to interact with gene promoter regions to modulate expression of immune-related genes in thymocytes',
                            'Stimulates T-lymphocyte maturation markers (CD3, CD4, CD8) in thymic cell cultures',
                            'Enhances thymic epithelial cell secretion of thymic hormones (thymulin, thymosin) in ex-vivo thymic tissue preparations',
                            'Modulates cytokine profiles in splenocyte cultures, shifting toward balanced Th1/Th2 responses',
                            'May interact with pattern recognition receptors on immune cells, though specific receptor identification is incomplete',
                        ],
                    ],
                ]),
                'preclinical_intro' => 'Thymagen has been studied primarily in Russian research institutions using immunosuppressed animal models and immune cell cultures.',
                'preclinical_subsections' => json_encode([
                    [
                        'title' => 'Immunomodulation Studies',
                        'findings' => [
                            ['title' => 'T-Cell Maturation', 'description' => 'In cyclophosphamide-immunosuppressed rodent models, Thymagen administration was associated with accelerated recovery of T-lymphocyte counts and restoration of T-cell subset ratios (CD4/CD8) toward normal values.'],
                            ['title' => 'Thymic Function', 'description' => 'In aged rodent models with involuted thymus glands, Thymagen treatment was reported to partially restore thymic cellularity and thymocyte proliferative responses to mitogens.'],
                        ],
                    ],
                    [
                        'title' => 'Gene Expression Studies',
                        'findings' => [
                            ['title' => 'Khavinson Epigenetic Hypothesis', 'description' => 'The Khavinson group has published studies suggesting that short peptides like Glu-Trp can interact directly with DNA in the minor groove, potentially influencing gene accessibility and transcription. This hypothesis requires further independent verification.'],
                            ['title' => 'Immune Gene Modulation', 'description' => 'Microarray analysis of Thymagen-treated splenocytes has shown modulation of immune-related gene clusters, though these studies predominantly originate from the developing laboratory and await independent confirmation.'],
                        ],
                    ],
                ]),
                'preclinical_disclaimer' => 'Most published research on Thymagen originates from the Khavinson laboratory in Russia. Independent replication by Western research groups is limited. Results should be interpreted with appropriate consideration of this context.',
                'human_use_intro' => 'Thymagen has been registered as a pharmaceutical preparation in Russia but has not undergone clinical evaluation by Western regulatory standards.',
                'human_use_subsections' => json_encode([['title' => 'Clinical Context', 'entries' => [['type' => 'content', 'value' => 'Thymagen has been registered in Russia for immunomodulatory applications. However, the clinical evidence base consists primarily of Russian-language publications that have not been independently replicated by international research groups, and the trials do not meet Western pharmaceutical regulatory standards (FDA, EMA).']]]]),
                'regulatory_subsections' => json_encode([['title' => 'Regulatory Status', 'entries' => [['type' => 'content', 'value' => 'Thymagen is registered as a pharmaceutical in Russia. It is not approved by the FDA, EMA, or other Western regulatory agencies. Research-grade Thymagen sold internationally is classified as a research chemical (RUO) and is not equivalent to the registered pharmaceutical preparation.']]]]),
                'regulatory_important_note' => 'Research-grade Thymagen is sold for in-vitro research purposes only. It is not approved by Western regulatory agencies for human therapeutic use.',
                'potential_applications_intro' => 'Published preclinical data suggests research applications in immunology and bioregulatory peptide biology.',
                'potential_applications' => json_encode([
                    ['title' => 'Thymic Biology Research', 'description' => 'Studying peptide-mediated modulation of thymocyte maturation and thymic epithelial cell function.'],
                    ['title' => 'Bioregulatory Peptide Research', 'description' => 'Investigating the Khavinson hypothesis of short peptide gene regulatory activity.'],
                ]),
                'potential_applications_important_context' => 'Applications are based primarily on research from the originating laboratory. Independent validation is needed.',
                'conclusion' => 'Thymagen (Glu-Trp) is a dipeptide from the Khavinson bioregulatory peptide program with proposed thymic immunomodulatory properties. The underlying concept — that short peptides derived from organ-specific extracts can restore function in those organs — is intriguing but remains insufficiently validated by independent Western research groups. While Thymagen has been registered as a pharmaceutical in Russia and has an extensive publication history in Russian-language journals, the absence of independent replication and Western regulatory evaluation limits the strength of conclusions that can be drawn. It remains a research tool for studying bioregulatory peptide biology and thymic immunomodulation.',
                'references' => json_encode([
                    ['title' => 'Bulletin of Experimental Biology and Medicine (2003)', 'authors' => 'Khavinson VKh.', 'links' => []],
                    ['title' => 'Peptides (2003)', 'authors' => 'Khavinson VKh, Morozov VG.', 'links' => []],
                ]),
                'key_points' => json_encode(['Thymagen (Glu-Trp) is a dipeptide thymic bioregulator from the Khavinson research program', 'Proposed to modulate T-lymphocyte maturation and thymic function', 'Registered as a pharmaceutical in Russia but not approved by Western regulators', 'Independent replication of findings is limited — research use only (RUO)']),
                'overview' => 'Thymagen is a dipeptide thymic bioregulator studied for T-lymphocyte maturation support and immunomodulation in the Khavinson bioregulatory peptide research framework.',
                'areas_of_research_intro' => 'Research focuses on thymic immunobiology and bioregulatory peptide science.',
                'areas_of_research' => json_encode([
                    ['name' => 'Thymic Immunobiology', 'description' => 'T-cell maturation and thymic function modulation'],
                    ['name' => 'Bioregulatory Peptides', 'description' => 'Short peptide gene regulatory activity research'],
                ]),
                'key_effects' => json_encode(['T-lymphocyte maturation support', 'Thymic cellularity modulation', 'Cytokine profile regulation', 'Proposed gene expression modulation']),
                'common_use_cases' => json_encode(['Thymic biology research', 'Bioregulatory peptide studies', 'Immunomodulation research']),
                'how_it_works' => 'Thymagen (Glu-Trp) is proposed to modulate thymic function through interaction with thymocytes and thymic epithelial cells, promoting T-lymphocyte maturation and thymic hormone secretion. The Khavinson hypothesis suggests direct peptide-DNA interactions in gene regulatory regions, though the specific molecular receptor and signaling pathway require further elucidation by independent research groups.',
                'rating' => '0.00',
                'rating_count' => 0,
            ],

            // ──────────────────────────────────────────────
            // 20. Vesilut
            // ──────────────────────────────────────────────
            'vesilut' => [
                'title' => 'Vesilut',
                'peptide_full_name' => 'L-Lysyl-L-Glutamyl-L-Aspartic Acid (KED Tripeptide)',
                'research_title' => 'Vesilut (Lys-Glu-Asp): A Comprehensive Research Overview of the Pineal Bioregulator',
                'research_outline' => 'An analysis of Vesilut, a synthetic tripeptide from the Khavinson bioregulatory peptide program, examining its proposed role as a pineal gland bioregulator and its effects on melatonin signaling research.',
                'education_tag' => 'Bioregulatory Peptides',
                'description' => 'Vesilut (Lys-Glu-Asp, KED tripeptide) is a synthetic peptide developed through the Khavinson bioregulatory peptide research program as a pineal gland bioregulator. It is proposed to support pineal function and melatonin-related signaling, with studies conducted primarily in aged animal models with declining pineal activity.',
                'molecular_formula' => 'C₁₅H₂₆N₄O₈',
                'molecular_weight' => '390.39 g/mol',
                'half_life' => 'Short (typical for unmodified small peptides)',
                'bioavailability' => 'Variable depending on route of administration in research settings',
                'background' => 'Vesilut is a tripeptide (Lys-Glu-Asp) from the Khavinson bioregulatory peptide program, classified as a pineal gland bioregulator. The pineal gland synthesizes and secretes melatonin, a hormone with circadian rhythm regulation, antioxidant, and immunomodulatory properties. Pineal function declines with aging, associated with reduced melatonin production, disrupted circadian rhythms, and altered immune function. The Khavinson program hypothesizes that organ-specific short peptides can restore function to aged or damaged tissues. Vesilut was developed as a synthetic analog of peptides extracted from pineal gland preparations, with the Lys-Glu-Asp sequence identified as an active component. In aged animal models, Vesilut has been studied for its effects on melatonin production, circadian gene expression, and general markers of aging. The compound has been registered as a dietary supplement in Russia. As with other Khavinson peptides, the research base originates predominantly from Russian institutions, and independent Western replication is limited.',
                'mechanism_of_action_intro' => 'Vesilut is proposed to act on pinealocytes and circadian signaling pathways to support melatonin synthesis and pineal gland homeostasis.',
                'mechanism_subsections' => json_encode([
                    [
                        'intro' => 'The proposed mechanism involves modulation of pinealocyte gene expression and melatonin biosynthesis enzyme activity.',
                        'points' => [
                            'Proposed to stimulate AANAT (arylalkylamine N-acetyltransferase) expression, the rate-limiting enzyme in melatonin biosynthesis',
                            'May modulate clock gene expression (Per1, Per2, Bmal1) in pinealocyte cultures, supporting circadian rhythm function',
                            'Reported to increase melatonin secretion from pineal gland explants of aged animals in ex-vivo culture systems',
                            'Khavinson hypothesis suggests direct interaction with gene regulatory regions in pinealocyte DNA',
                            'May support antioxidant enzyme expression in pineal tissue, protecting against age-related oxidative damage',
                        ],
                    ],
                ]),
                'preclinical_intro' => 'Vesilut has been studied in aged animal models and pineal gland tissue preparations, primarily at the Saint Petersburg Institute of Bioregulation and Gerontology.',
                'preclinical_subsections' => json_encode([
                    [
                        'title' => 'Pineal Function Studies',
                        'findings' => [
                            ['title' => 'Melatonin Production', 'description' => 'In aged rodent models, Vesilut administration was associated with increased nocturnal melatonin levels as measured by serum ELISA and urinary 6-sulfatoxymelatonin excretion, suggesting partial restoration of age-declined melatonin production.'],
                            ['title' => 'Pineal Gland Histology', 'description' => 'Histological examination of pineal glands from aged Vesilut-treated animals showed reduced lipofuscin accumulation and improved pinealocyte morphology compared to age-matched untreated controls.'],
                        ],
                    ],
                    [
                        'title' => 'Circadian and Aging Studies',
                        'findings' => [
                            ['title' => 'Circadian Gene Expression', 'description' => 'In pineal tissue explants, Vesilut treatment was reported to modulate expression of circadian clock genes, though these findings are from the originating laboratory and require independent confirmation.'],
                            ['title' => 'Lifespan Studies', 'description' => 'The Khavinson group has published studies in which bioregulatory peptide administration (including Vesilut) was associated with extended median lifespan in aged rodent cohorts, though these studies have not been independently replicated.'],
                        ],
                    ],
                ]),
                'preclinical_disclaimer' => 'Most research on Vesilut originates from the Khavinson laboratory. Independent replication by international research groups is limited. Results should be interpreted with this important caveat.',
                'human_use_intro' => 'No clinical trials meeting Western regulatory standards have been published for Vesilut.',
                'human_use_subsections' => json_encode([['title' => 'Clinical Evidence', 'entries' => [['type' => 'content', 'value' => 'Vesilut has been used in Russia as a dietary supplement. Clinical evidence consists of Russian-language publications from the originating research group, which have not been independently verified by international research groups or evaluated by Western regulatory agencies.']]]]),
                'regulatory_subsections' => json_encode([['title' => 'Regulatory Status', 'entries' => [['type' => 'content', 'value' => 'Vesilut is registered as a dietary supplement in Russia. It is not approved by the FDA, EMA, or other Western regulatory agencies as a pharmaceutical. Research-grade Vesilut sold internationally is for laboratory research purposes only (RUO).']]]]),
                'regulatory_important_note' => 'Research-grade Vesilut is sold for in-vitro research purposes only. It is not approved by Western regulatory agencies.',
                'potential_applications_intro' => 'Published data suggests research applications in pineal biology and circadian rhythm research.',
                'potential_applications' => json_encode([
                    ['title' => 'Pineal Biology Research', 'description' => 'Studying peptide-mediated modulation of melatonin biosynthesis and pinealocyte function.'],
                    ['title' => 'Circadian Rhythm Research', 'description' => 'Investigating bioregulatory peptide effects on clock gene expression and circadian signaling.'],
                ]),
                'potential_applications_important_context' => 'Applications are based primarily on research from the originating laboratory. Independent validation is needed.',
                'conclusion' => 'Vesilut (Lys-Glu-Asp) is a tripeptide from the Khavinson bioregulatory program proposed to function as a pineal gland bioregulator. The concept of supporting age-declined melatonin production through targeted peptide intervention is scientifically interesting, and the published preclinical data from Russian institutions suggests effects on melatonin levels and pineal histology. However, the critical limitation remains the absence of independent replication by Western research groups and evaluation by internationally recognized regulatory standards. Vesilut serves as a research tool for studying bioregulatory peptide biology and pineal gland function in laboratory settings.',
                'references' => json_encode([
                    ['title' => 'Advances in Gerontology (2010)', 'authors' => 'Khavinson VKh et al.', 'links' => []],
                    ['title' => 'Bulletin of Experimental Biology and Medicine (2005)', 'authors' => 'Khavinson VKh, Anisimov VN.', 'links' => []],
                ]),
                'key_points' => json_encode(['Vesilut (Lys-Glu-Asp) is a tripeptide pineal bioregulator from the Khavinson program', 'Proposed to support melatonin biosynthesis and pineal function in aged models', 'Registered as a dietary supplement in Russia; not Western-approved', 'Independent replication is limited — research use only (RUO)']),
                'overview' => 'Vesilut is a tripeptide pineal bioregulator studied for melatonin biosynthesis support and circadian rhythm research in the Khavinson bioregulatory framework.',
                'areas_of_research_intro' => 'Research focuses on pineal biology, melatonin production, and bioregulatory peptide science.',
                'areas_of_research' => json_encode([
                    ['name' => 'Pineal Biology', 'description' => 'Melatonin biosynthesis and pinealocyte function'],
                    ['name' => 'Circadian Research', 'description' => 'Clock gene expression and circadian signaling'],
                    ['name' => 'Bioregulatory Peptides', 'description' => 'Khavinson peptide gene regulatory hypothesis'],
                ]),
                'key_effects' => json_encode(['Proposed melatonin synthesis support', 'Pinealocyte function modulation', 'Circadian gene expression effects', 'Antioxidant enzyme support']),
                'common_use_cases' => json_encode(['Pineal gland research', 'Melatonin biology studies', 'Bioregulatory peptide investigations']),
                'how_it_works' => 'Vesilut (Lys-Glu-Asp) is proposed to modulate pinealocyte function by stimulating AANAT expression (the rate-limiting melatonin synthesis enzyme) and supporting clock gene expression. The Khavinson hypothesis suggests direct peptide-DNA interaction at gene regulatory sequences in pinealocytes, though the precise molecular receptor and signaling pathway remain to be fully characterized by independent research.',
                'rating' => '0.00',
                'rating_count' => 0,
            ],

            // ──────────────────────────────────────────────
            // 21. Prostamax
            // ──────────────────────────────────────────────
            'prostamax' => [
                'title' => 'Prostamax',
                'peptide_full_name' => 'L-Lysyl-L-Glutamyl-L-Aspartyl-L-Proline (KEDP Tetrapeptide)',
                'research_title' => 'Prostamax (Lys-Glu-Asp-Pro): A Comprehensive Research Overview of the Prostate Bioregulator',
                'research_outline' => 'An analysis of Prostamax, a synthetic tetrapeptide from the Khavinson bioregulatory peptide program, examining its proposed role as a prostate tissue bioregulator in preclinical research models.',
                'education_tag' => 'Bioregulatory Peptides',
                'description' => 'Prostamax (Lys-Glu-Asp-Pro, KEDP tetrapeptide) is a synthetic peptide from the Khavinson bioregulatory peptide research program, classified as a prostate tissue bioregulator. It is proposed to modulate gene expression and cellular function in prostate epithelial cells, with studies conducted primarily in aged animal models with prostate tissue changes.',
                'molecular_formula' => 'C₂₀H₃₃N₅O₉',
                'molecular_weight' => '487.51 g/mol',
                'half_life' => 'Short (typical for unmodified small peptides)',
                'bioavailability' => 'Variable depending on route of administration in research settings',
                'background' => 'Prostamax is a tetrapeptide (Lys-Glu-Asp-Pro) developed through the Khavinson bioregulatory peptide research program at the Saint Petersburg Institute of Bioregulation and Gerontology. The program\'s foundational hypothesis is that short peptides (2-4 amino acids) extracted from specific organs possess tissue-specific bioregulatory activity, capable of restoring or maintaining function in the target tissue through gene expression modulation. Prostamax was derived from research on prostate gland extracts, with the KEDP tetrapeptide sequence identified as an active component in prostate cell culture assays. The prostate gland undergoes significant age-related changes, including benign proliferative changes affecting the majority of aging males. The Khavinson group has investigated Prostamax for its effects on prostate epithelial cell proliferation, apoptosis markers, and tissue homeostasis in aged animal models. The peptide has been registered in Russia as a dietary supplement. As with other Khavinson bioregulatory peptides, the research base originates predominantly from Russian institutions.',
                'mechanism_of_action_intro' => 'Prostamax is proposed to modulate prostate epithelial cell gene expression and tissue homeostasis through the Khavinson bioregulatory mechanism.',
                'mechanism_subsections' => json_encode([
                    [
                        'intro' => 'The proposed mechanism involves tissue-specific gene expression modulation in prostate epithelial cells.',
                        'points' => [
                            'Proposed to interact with gene regulatory regions in prostate epithelial cell DNA, modulating transcription of tissue homeostasis genes',
                            'Reported to normalize proliferation/apoptosis balance in prostate epithelial cell cultures from aged animals',
                            'May modulate expression of androgen receptor-related genes and growth factor signaling in prostate tissue',
                            'Reported to reduce inflammatory cytokine expression in prostate tissue explants from aged animals',
                            'Khavinson hypothesis suggests direct peptide-DNA minor groove interaction as the primary signaling mechanism',
                        ],
                    ],
                ]),
                'preclinical_intro' => 'Prostamax has been studied in prostate cell cultures, aged animal models, and tissue explant preparations at Russian research institutions.',
                'preclinical_subsections' => json_encode([
                    [
                        'title' => 'Prostate Tissue Studies',
                        'findings' => [
                            ['title' => 'Cell Proliferation Markers', 'description' => 'In prostate tissue from aged rodents, Prostamax administration was associated with normalized Ki-67 proliferation index values and increased apoptotic index (TUNEL staining), suggesting restoration of proliferation/apoptosis balance.'],
                            ['title' => 'Inflammatory Markers', 'description' => 'Prostate tissue from aged Prostamax-treated animals showed reduced expression of inflammatory markers (COX-2, IL-6) compared to age-matched controls, suggesting anti-inflammatory activity in the prostate microenvironment.'],
                        ],
                    ],
                    [
                        'title' => 'Gene Expression Studies',
                        'findings' => [
                            ['title' => 'Tissue Homeostasis Genes', 'description' => 'The Khavinson group reported modulation of genes involved in cell cycle regulation and apoptosis in prostate tissue from treated animals, though these findings originate from the developing laboratory.'],
                            ['title' => 'Peptide-DNA Interaction', 'description' => 'Molecular modeling studies from the Khavinson group propose that the KEDP sequence interacts with specific DNA minor groove regions in prostate-related gene promoters, though this mechanism requires experimental validation by independent groups.'],
                        ],
                    ],
                ]),
                'preclinical_disclaimer' => 'Most research on Prostamax originates from the Khavinson laboratory in Russia. Independent replication by international research groups is very limited. Results require independent confirmation.',
                'human_use_intro' => 'No clinical trials meeting Western regulatory standards have been published for Prostamax.',
                'human_use_subsections' => json_encode([['title' => 'Clinical Evidence', 'entries' => [['type' => 'content', 'value' => 'Prostamax has been used in Russia as a dietary supplement for prostate health. Clinical evidence consists of Russian-language publications from the originating research group. No studies meeting FDA or EMA clinical trial standards have been published.']]]]),
                'regulatory_subsections' => json_encode([['title' => 'Regulatory Status', 'entries' => [['type' => 'content', 'value' => 'Prostamax is registered as a dietary supplement in Russia. It is not approved by the FDA, EMA, or other Western regulatory agencies. Research-grade Prostamax sold internationally is classified as a research chemical (RUO).']]]]),
                'regulatory_important_note' => 'Research-grade Prostamax is sold for in-vitro research purposes only. It is not approved by Western regulatory agencies and is not intended as a treatment for any condition.',
                'potential_applications_intro' => 'Published data from the originating laboratory suggests research applications in prostate biology and bioregulatory peptide science.',
                'potential_applications' => json_encode([
                    ['title' => 'Prostate Biology Research', 'description' => 'Studying peptide-mediated modulation of prostate epithelial cell homeostasis and gene expression.'],
                    ['title' => 'Bioregulatory Peptide Research', 'description' => 'Investigating the Khavinson hypothesis of tissue-specific short peptide bioregulation.'],
                ]),
                'potential_applications_important_context' => 'Applications are based primarily on research from the originating laboratory. Independent validation by international groups is essential.',
                'conclusion' => 'Prostamax (Lys-Glu-Asp-Pro) is a tetrapeptide from the Khavinson bioregulatory program proposed to function as a prostate tissue bioregulator. The published preclinical data from Russian institutions suggests effects on prostate cell proliferation markers and inflammatory gene expression in aged animal models. However, the fundamental limitation of the Khavinson peptide program applies — the research originates predominantly from a single laboratory, and independent replication by Western research groups meeting international regulatory standards has not been achieved. The proposed mechanism of direct peptide-DNA interaction, while conceptually interesting, requires rigorous independent validation. Prostamax remains an investigational research tool for studying bioregulatory peptide biology in the specific context of prostate tissue homeostasis.',
                'references' => json_encode([
                    ['title' => 'Bulletin of Experimental Biology and Medicine (2006)', 'authors' => 'Khavinson VKh et al.', 'links' => []],
                    ['title' => 'Advances in Gerontology (2011)', 'authors' => 'Khavinson VKh, Linkova NS.', 'links' => []],
                ]),
                'key_points' => json_encode(['Prostamax (Lys-Glu-Asp-Pro) is a tetrapeptide prostate bioregulator from the Khavinson program', 'Proposed to normalize prostate epithelial proliferation/apoptosis balance', 'Registered as a dietary supplement in Russia; not Western-approved', 'Independent replication is very limited — research use only (RUO)']),
                'overview' => 'Prostamax is a tetrapeptide prostate bioregulator studied for prostate epithelial cell homeostasis in the Khavinson bioregulatory peptide research framework.',
                'areas_of_research_intro' => 'Research focuses on prostate biology, tissue homeostasis, and bioregulatory peptide science.',
                'areas_of_research' => json_encode([
                    ['name' => 'Prostate Biology', 'description' => 'Epithelial cell homeostasis and proliferation regulation'],
                    ['name' => 'Bioregulatory Peptides', 'description' => 'Tissue-specific short peptide bioregulation'],
                ]),
                'key_effects' => json_encode(['Proposed proliferation/apoptosis normalization', 'Inflammatory marker reduction', 'Prostate tissue homeostasis support', 'Proposed gene expression modulation']),
                'common_use_cases' => json_encode(['Prostate biology research', 'Bioregulatory peptide studies', 'Tissue homeostasis investigations']),
                'how_it_works' => 'Prostamax (Lys-Glu-Asp-Pro) is proposed to modulate prostate epithelial cell function through the Khavinson bioregulatory mechanism — direct peptide-DNA interaction at gene regulatory regions to influence transcription of tissue homeostasis, cell cycle, and inflammatory genes. The precise molecular receptor and signal transduction pathway remain to be fully characterized by independent research groups.',
                'rating' => '0.00',
                'rating_count' => 0,
            ],

        ];
    }
}
